Invitae (NVTAQ) 10-Q 4 Aug 20 2020 Q2 Quarterly report Financial data

Cover Page

Cover Page - shares	6 Months Ended
	Jun. 30, 2020	Jul. 31, 2020
Cover [Abstract]
Entity Registrant Name	Invitae Corp
Document Type	10-Q
Document Period End Date	Jun. 30, 2020
Current Fiscal Year End Date	--12-31
Document Quarterly Report	true
Document Transition Report	false
Title of 12(b) Security	Common Stock, $0.0001 par value per share
Trading Symbol	NVTA
Security Exchange Name	NYSE
Entity Incorporation, State or Country Code	DE
Entity Central Index Key	0001501134
Entity File Number	001-36847
Amendment Flag	false
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		131,785,131
Document Fiscal Year Focus	2020
Document Fiscal Period Focus	Q2
Entity Tax Identification Number	27-1701898
Entity Address, Address Line One	1400 16th Street
Entity Address, City or Town	San Francisco
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	94103
City Area Code	415
Local Phone Number	374-7782

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Jun. 30, 2020	Dec. 31, 2019
Current assets:
Cash and cash equivalents	$ 168,203	$ 151,389
Marketable securities	253,933	240,436
Accounts receivable	27,905	32,541
Prepaid expenses and other current assets	21,081	18,032
Total current assets	471,122	442,398
Property and equipment, net	43,381	37,747
Operating lease assets	38,239	36,640
Restricted cash	6,343	6,183
Intangible assets, net	192,644	125,175
Goodwill	211,225	126,777
Other assets	6,921	6,681
Total assets	969,875	781,601
Current liabilities:
Accounts payable	20,091	10,321
Accrued liabilities	99,490	64,814
Operating lease obligations	6,339	4,870
Finance lease obligations	977	1,855
Total current liabilities	126,897	81,860
Operating lease obligations, net of current portion	42,134	42,191
Finance lease obligations, net of current portion	879	1,155
Convertible senior notes, net	276,092	268,755
Deferred tax liability	10,250	0
Other long-term liabilities	49,428	8,000
Total liabilities	505,680	401,961
Commitments and contingencies (Note 8)
Stockholders’ equity:
Common stock	13	10
Accumulated other comprehensive income (loss)	572	(9)
Additional paid-in capital	1,487,217	1,138,316
Accumulated deficit	(1,023,607)	(758,677)
Total stockholders’ equity	464,195	379,640
Total liabilities and stockholders’ equity	$ 969,875	$ 781,601

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Revenue:
Total revenue	$ 46,191	$ 53,475	$ 110,439	$ 94,028
Cost of revenue	42,952	28,006	83,374	49,260
Research and development	74,963	25,302	130,631	43,296
Selling and marketing	39,520	30,779	81,640	54,972
General and administrative	30,838	21,274	54,660	34,593
Loss from operations	(142,082)	(51,886)	(239,866)	(88,093)
Other income (expense), net	(21,436)	1,381	(16,728)	2,019
Interest expense	(5,485)	(2,121)	(10,936)	(4,229)
Net loss before taxes	(169,003)	(52,626)	(267,530)	(90,303)
Income tax benefit	(2,600)	(3,950)	(2,600)	(3,950)
Net loss	$ (166,403)	$ (48,676)	$ (264,930)	$ (86,353)
Net loss per share, basic and diluted (in dollars per share)	$ (1.29)	$ (0.54)	$ (2.35)	$ (1.01)
Shares used in computing net loss per share, basic and diluted	129,023	90,863	112,765	85,148
Test revenue
Revenue:
Total revenue	$ 45,099	$ 52,302	$ 108,177	$ 91,921
Other revenue
Revenue:
Total revenue	$ 1,092	$ 1,173	$ 2,262	$ 2,107

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Comprehensive Loss - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Statement of Comprehensive Income [Abstract]
Net loss	$ (166,403)	$ (48,676)	$ (264,930)	$ (86,353)
Other comprehensive income:
Unrealized income (loss) on available-for-sale marketable securities, net of tax	(722)	(8)	581	5
Comprehensive loss	$ (167,125)	$ (48,684)	$ (264,349)	$ (86,348)

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Stockholders' Equity - USD ($) $ in Thousands	Total	Common stock:	Accumulated other comprehensive income (loss):	Additional paid-in capital:	Accumulated deficit:	Restatement adjustmentAdditional paid-in capital:
Balance, beginning of period at Dec. 31, 2018		$ 8	$ (5)	$ 678,548	$ (516,712)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Common stock issued		1		184,490
Unrealized income (loss) on available-for-sale marketable securities, net of tax	$ 5		5
Common stock issued on exercise of stock options, net				2,432
Common stock issued pursuant to exercises of warrants				113
Common stock issued pursuant to employee stock purchase plan				2,578
Common stock issued or issuable pursuant to business combinations				59,442
Stock-based compensation expense				16,956
Net loss	(86,353)
Balance, end of period at Jun. 30, 2019	341,503	9	0	944,559	(603,065)
Balance, beginning of period at Mar. 31, 2019		9	8	870,784	(554,389)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Unrealized income (loss) on available-for-sale marketable securities, net of tax	(8)		(8)
Common stock issued on exercise of stock options, net				413
Common stock issued pursuant to exercises of warrants				25
Common stock issued pursuant to employee stock purchase plan				2,578
Common stock issued or issuable pursuant to business combinations				59,026
Stock-based compensation expense				11,733
Net loss	(48,676)				(48,676)
Balance, end of period at Jun. 30, 2019	341,503	9	0	944,559	(603,065)
Balance, beginning of period at Dec. 31, 2019	379,640	10	(9)	1,138,316	(758,677)
Balance, beginning of period (Immaterial error related to classification of Indemnification from acquisition) at Dec. 31, 2019						$ (10,387)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Common stock issued		3		217,486
Unrealized income (loss) on available-for-sale marketable securities, net of tax	581		581
Common stock issued on exercise of stock options, net				2,171
Common stock issued pursuant to exercises of warrants				62
Common stock issued pursuant to employee stock purchase plan				4,527
Common stock issued or issuable pursuant to business combinations				102,506
Stock-based compensation expense				32,536
Net loss	(264,930)
Balance, end of period at Jun. 30, 2020	464,195	13	572	1,487,217	(1,023,607)
Balance, beginning of period at Mar. 31, 2020		10	1,294	1,182,033	(857,204)
Balance, beginning of period (Immaterial error related to classification of Indemnification from acquisition) at Mar. 31, 2020						$ (10,400)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Common stock issued		3		217,486
Unrealized income (loss) on available-for-sale marketable securities, net of tax	(722)		(722)
Common stock issued on exercise of stock options, net				1,026
Common stock issued pursuant to exercises of warrants				35
Common stock issued pursuant to employee stock purchase plan				4,527
Common stock issued or issuable pursuant to business combinations				60,053
Stock-based compensation expense				22,057
Net loss	(166,403)				(166,403)
Balance, end of period at Jun. 30, 2020	$ 464,195	$ 13	$ 572	$ 1,487,217	$ (1,023,607)

Condensed Consolidated Statem_4

Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019
Cash flows from operating activities:
Net loss	$ (264,930)	$ (86,353)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	14,500	6,725
Stock-based compensation	81,124	19,540
Amortization of debt discount and issuance costs	7,337	0
Remeasurements of liabilities associated with business combinations	26,749	(286)
Benefit from income taxes	(2,600)	(3,950)
Other	(536)	1,182
Changes in operating assets and liabilities, net of businesses acquired:
Accounts receivable	4,939	3,153
Prepaid expenses and other current assets	(3,049)	(3,825)
Other assets	942	2,410
Accounts payable	9,185	(3,954)
Accrued expenses and other liabilities	3,585	4,267
Net cash used in operating activities	(122,754)	(61,091)
Cash flows from investing activities:
Purchases of marketable securities	(115,350)	(20,781)
Proceeds from sales of marketable securities	12,532	0
Proceeds from maturities of marketable securities	89,965	34,000
Acquisition of businesses, net of cash acquired	(57,576)	3,193
Purchases of property and equipment	(10,854)	(8,824)
Other	(1,334)	0
Net cash provided by (used in) investing activities	(82,617)	7,588
Cash flows from financing activities:
Proceeds from public offerings of common stock, net	217,489	184,490
Proceeds from issuance of common stock, net	6,760	5,123
Finance lease principal payments	(1,154)	(1,031)
Other	(750)	0
Net cash provided by financing activities	222,345	188,582
Net increase in cash, cash equivalents and restricted cash	16,974	135,079
Cash, cash equivalents and restricted cash at beginning of period	157,572	118,164
Cash, cash equivalents and restricted cash at end of period	174,546	253,243
Supplemental cash flow information of non-cash investing and financing activities:
Purchases of property and equipment in accounts payable and accrued liabilities	1,570	1,059
Common stock issued for acquisition of businesses	75,682	59,442
Consideration payable for acquisition of businesses	16,813	0
Operating lease assets obtained in exchange for lease obligations, net	$ 4,046	$ 5,615

Organization and description of

Organization and description of business	6 Months Ended
	Jun. 30, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization and description of business	Organization and description of business Invitae Corporation ("Invitae," “the Company," "we," "us," and "our") was incorporated in the State of Delaware on January 13, 2010, as Locus Development, Inc. and changed its name to Invitae Corporation in 2012. We utilize an integrated portfolio of laboratory processes, software tools and informatics capabilities to process DNA-containing samples, analyze information about patient-specific genetic variation and generate test reports for clinicians and patients. Our main production facility is located in San Francisco, California. We currently have more than 20,000 genes in production and provide a variety of diagnostic tests that can be used in multiple indications. We offer genetic testing across multiple clinical areas, including hereditary cancer, cardiology, neurology, pediatrics, metabolic conditions and rare diseases. To augment our offering and realize our mission, we acquired multiple assets including four businesses in 2017, which expanded our suite of genome management offerings and expanded our offering in reproductive health. In the first quarter of 2019, we introduced our non-invasive prenatal screen ("NIPS"). In June 2019, we launched a direct channel to consumers to increase accessibility to our testing platform. To improve our technology stack and reduce costs associated with variant interpretation, we acquired Singular Bio, Inc. ("Singular Bio") in June 2019, Jungla Inc. ("Jungla") in July 2019, and Oracle BV operating under the name "Diploid" in March 2020. To further expand our ability to scale and improve customer experience with patient support telehealth solutions and the use of chatbots, we acquired Clear Genetics, Inc. ("Clear Genetics") in November 2019. In April 2020, we acquired YouScript Incorporated ("YouScript") and Genelex Solutions, LLC ("Genelex") to expand content and improve customer experience by bringing pharmacogenetic testing and integrated clinical decision support to Invitae. In order to expand content and increase access to personalized oncology, we entered into a definitive agreement to acquire ArcherDX, Inc. ("ArcherDX") in June 2020 which we expect to close in the next few months, with a view towards integrating Invitae's germline testing with ArcherDX's tumor profiling and liquid biopsy technology and services into a single platform to enable precision medicine approaches from diagnostic testing to therapy optimization and monitoring. Invitae operates in one segment. Basis of presentation The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”) for interim financial information and in accordance with the instructions to Form 10-Q and Rule 10-01 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements. The unaudited interim condensed consolidated financial statements have been prepared on the same basis as the annual financial statements. In the opinion of management, the accompanying unaudited condensed consolidated financial statements reflect all adjustments (consisting only of normal recurring adjustments) considered necessary for a fair presentation. The information included in this Quarterly Report on Form 10-Q should be read in conjunction with the audited financial statements and notes thereto included in our Annual Report on Form 10-K for the year ended December 31, 2019 . The results for the three and six months ended June 30, 2020

Summary of significant accounti

Summary of significant accounting policies	6 Months Ended
	Jun. 30, 2020
Accounting Policies [Abstract]
Summary of significant accounting policies	Summary of significant accounting policies Principles of consolidation Our unaudited condensed consolidated financial statements include our accounts and the accounts of our wholly-owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation. Use of estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make judgments, estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities as of the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. We base these estimates on current facts, historical and anticipated results, trends and various other assumptions that we believe are reasonable under the circumstances, including assumptions as to future events. Actual results could differ materially from those judgments, estimates and assumptions. We evaluate our estimates on an ongoing basis. Concentrations of credit risk and other risks and uncertainties Financial instruments that potentially subject us to a concentration of credit risk consist of cash, cash equivalents, marketable securities and accounts receivable. Our cash and cash equivalents are held by financial institutions in the United States. Such deposits may exceed federally insured limits. Significant customers are those that represent 10% or more of our total revenue presented on the consolidated statements of operations. Our revenue from significant customers as a percentage of our total revenue was as follows: Three Months Ended June 30, Six Months Ended June 30, 2020 2019 2020 2019 Medicare 20 % 23 % 21 % 22 % United Healthcare * 10 % * 10 % * Balance represents less than 10% of total revenue Cash, cash equivalents and restricted cash The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the consolidated balance sheets that sum to the total of the same amounts shown in the statements of cash flows (in thousands): June 30, December 31, Cash and cash equivalents $ 168,203 $ 151,389 Restricted cash 6,343 6,183 Total cash, cash equivalents and restricted cash $ 174,546 $ 157,572 Inventory We maintain test reagents and other consumables primarily used in sample collection kits which are valued at the lower of cost or net realizable value. Cost is determined using actual costs on a first-in, first-out basis. Our inventory was $11.1 million and $6.6 million as of June 30, 2020 and December 31, 2019 , respectively, and was recorded in prepaid expenses and other current assets on our consolidated balance sheets. While we have not experienced significant disruption in our supply chain and we do not yet know the full impact COVID-19 will have on our supply chain, we have increased our inventory on hand to respond to potential future disruptions that may occur. Fair value of financial instruments Our financial instruments consist principally of cash and cash equivalents, marketable securities, accounts payable, accrued liabilities, finance leases and liabilities associated with business combinations. The carrying amounts of certain of these financial instruments, including cash and cash equivalents, accounts receivable, accounts payable and accrued and other current liabilities approximate their current fair value due to the relatively short-term nature of these accounts. Based on borrowing rates available to us, the carrying value of our finance leases approximate their fair values. Liabilities associated with business combinations are recorded at their estimated fair value. Prior period reclassifications We have reclassified certain amounts in prior periods to conform with current presentation. Immaterial correction of an error We determined the historical classification of certain acquisition-related obligations as equity and the subsequent measurement of such obligations was inappropriate and instead should have been classified as liabilities and subsequently measured at fair value with changes recognized in other income (expense), net during the three months ended March 31, 2020. We determined that the impact of the error to previously issued financial statements was not material and have corrected the immaterial error in the three months ended March 31, 2020. The impact of this correction was an increase to other long-term liabilities of $10.1 million , a corresponding decrease to additional paid-in capital of $10.4 million and an increase to other income, net of $0.3 million . Recent accounting pronouncements We evaluate all Accounting Standards Updates (“ASUs”) issued by the Financial Accounting Standards Board ("FASB") for consideration of their applicability. ASUs not included in the disclosures in this report were assessed and determined to be either not applicable or are not expected to have a material impact on our consolidated financial statements. Recently adopted accounting pronouncements In June 2016, FASB issued ASU 2016-13, Financial Instruments-Credit Losses (Topic 326), which requires measurement and recognition of expected credit losses for financial assets. This guidance became effective for us beginning in the first quarter of 2020 and was adopted using a modified retrospective approach, with certain exceptions. The adoption of Topic 326 did not have a material impact on our consolidated financial statements as credit losses are not expected to be significant. As part of our adoption of Topic 326, we assess our accounts receivables for expected credit losses at each reporting period by disaggregating by payer type and further by portfolios of customers with similar characteristics, such as customer type and geographic location. We then review each portfolio for expected credit losses based on historical payment trends as well as forward looking data and current economic trends. If a credit loss is determined, we record a reduction to our accounts receivable balance with a corresponding general and administrative expense.

Revenue, accounts receivable an

Revenue, accounts receivable and deferred revenue	6 Months Ended
	Jun. 30, 2020
Revenue from Contract with Customer [Abstract]
Revenue, accounts receivable and deferred revenue	Revenue, accounts receivable and deferred revenue Test revenue is generated from sales of diagnostic tests to three groups of customers: institutions, such as hospitals, clinics and partners; patients who pay directly; and patients’ insurance carriers. Amounts billed and collected, and the timing of collections, vary based on whether the payer is an institution, a patient or an insurance carrier. Other revenue consists principally of revenue recognized under collaboration and genome network agreements and is accounted for under the provisions provided in ASC 606, Revenue from Contracts with Customers . The following table includes our revenues as disaggregated by payer category (in thousands): Three Months Ended June 30, Six Months Ended June 30, 2020 2019 2020 2019 Test revenue: Institutions $ 9,531 $ 9,814 $ 23,028 $ 17,968 Patient - direct 4,298 4,056 10,089 7,797 Patient - insurance 31,270 38,432 75,060 66,156 Total test revenue 45,099 52,302 108,177 91,921 Other revenue 1,092 1,173 2,262 2,107 Total revenue $ 46,191 $ 53,475 $ 110,439 $ 94,028 We recognize revenue related to billings based on estimates of the amount that will ultimately be realized. Cash collections for certain diagnostic tests delivered may differ from rates originally estimated. As a result of new information, we updated our estimate of the amounts to be recognized for previously delivered tests which resulted in the following increases to revenue and decreases to our loss from operations and basic and diluted net loss per share (in millions, except per share amounts): Three Months Ended June 30, Six Months Ended June 30, 2020 2019 2020 2019 Revenue $ 0.9 $ 2.4 $ 2.3 $ 2.8 Loss from operations $ (0.9 ) $ (2.4 ) $ (2.3 ) $ (2.8 ) Net loss per share, basic and diluted $ (0.01 ) $ (0.03 ) $ (0.02 ) $ (0.03 ) Influence of COVID-19 Our test volumes decreased significantly in the second half of March 2020 as compared to the first few months of 2020 as a result of COVID-19 and related limitations and priorities across the healthcare system. While it is too early to predict the full impact COVID-19 will have on our business, our test volumes have increased in April, May and June 2020 from the low in March 2020, although we are currently still experiencing reduced test volumes and changes in product mix due to the impact of COVID-19. We expect COVID-19 to have a material impact on our financial results for at least the next quarter and for the foreseeable future. We have reviewed and adjusted for the impact of COVID-19 on our estimates related to revenue recognition and expected credit losses. Approximately 8% of our workforce as of March 31, 2020 was impacted by a reduction in force in April 2020 in an initiative to manage costs and cash burn that resulted in one-time costs in the second quarter of 2020 of $3.8 million . In addition, effective May 2020, we have reduced the salaries of our named executive officers by approximately 20% . On March 27, 2020, the Coronavirus Aid, Relief, and Economic Security Act ("CARES Act") was signed into law which was a stimulus bill intended to bolster the economy, among other things, and provide assistance to qualifying businesses and individuals. The CARES Act included an infusion of funds into the healthcare system, and in April 2020, we received $3.8 million as a part of this initiative. This payment was recognized as other income (expense), net in our consolidated statement of operations during the three months ended June 30, 2020. At this time, we are not certain of the availability, extent or impact of any future relief provided under the CARES Act. Accounts receivable The majority of our accounts receivable represents amounts billed to institutions (e.g., hospitals, clinics, partners) and estimated amounts to be collected from third-party insurance payers for diagnostic test revenue recognized. Also included are amounts due under the terms of collaboration and genome network agreements for diagnostic testing and data aggregation reporting services provided and proprietary platform access rights transferred. Deferred revenue We record deferred revenue when cash payments are received or due in advance of our performance related to one or more performance obligations. The amounts deferred to date primarily consist of prepayments related to our consumer direct channel as well as consideration received pertaining to the estimated exercise of certain re-requisition rights. In order to comply with loss contract rules, our re-requisition rights revenue deferral is no less than the estimated cost of fulfilling related obligations. We recognize revenue related to re-requisition rights as the rights are exercised or expire unexercised, which is generally within 90 days of initial deferral.

Business combinations

Business combinations	6 Months Ended
	Jun. 30, 2020
Business Combinations [Abstract]
Business combinations	Business combinations Singular Bio In June 2019, we acquired 100% of the fully diluted equity of Singular Bio, a privately held company developing single molecule detection technology, for approximately $57.3 million , comprised of $53.9 million in the form of 2.5 million shares of our common stock and the remainder in cash. We granted approximately $90.0 million of restricted stock units ("RSU") under our 2015 Stock Incentive Plan as inducement awards to new employees who joined Invitae in connection with our acquisition of Singular Bio. $45.0 million of the RSUs are time-based and vest in three equal installments in December 2019, June 2020, and December 2020, subject to the employee's continued service with us ("Time-based RSUs") and $45.0 million of the RSUs are performance-based RSUs ("PRSUs") that vest upon the achievement of certain performance conditions. Since the number of awards granted is based on a 30-day volume weighted-average share price with a fixed dollar value, these Time-based RSUs and PRSUs are liability-classified and the fair value is estimated at each reporting period based on the number of shares that are expected to be issued at each reporting date and our closing stock price, which combined are categorized as Level 3 inputs. Therefore, fair value of the RSUs and PRSUs and the number of shares to be issued will not be fixed until the awards vest. During the three and six months ended June 30, 2020 , we recorded research and development stock-based compensation expense of $10.9 million and $18.5 million , respectively, related to the Time-based RSUs, and $18.9 million and $30.1 million , respectively, related to the PRSUs based on our evaluations of the probability of achieving performance conditions. As of June 30, 2020 , the Time-based RSUs and PRSUs had a total fair value of $48.6 million and $54.4 million , respectively, based on a total estimated issuance of 4.4 million shares and expectation of the achievement of the performance conditions. During the three and six months ended June 30, 2020 , 0.9 million of the Time-based RSUs and 0.6 million of the PRSUs vested with a total fair value of $26.8 million which was recorded in common stock issued or issuable pursuant to business combinations in the consolidated statements of stockholders' equity. Jungla In July 2019, we acquired 100% of the equity interest of Jungla, a privately held company developing a platform for molecular evidence testing in genes, for approximately $59.0 million , comprised of $44.9 million in the form of shares of our common stock and the remainder in cash. We agreed to pay a portion of the cash and issue approximately 0.2 million shares of our common stock after a 12-month period, subject to a hold back to satisfy indemnification obligations that may arise. We may be required to pay contingent consideration based on achievement of post-closing development milestones. As of the acquisition date, the fair value of this contingent consideration was $10.7 million including cash and common stock. The milestones are expected to be completed within two years . The material factors that may impact the fair value of the contingent consideration, and therefore, this liability, are the probabilities and timing of achieving the related milestones and the discount rate we used to estimate the fair value. Significant changes in any of the probabilities of success would result in a significant change in the fair value, which will be estimated at each reporting date with changes reflected as a general and administrative expense. As of June 30, 2020 , we had a stock payable liability related to our acquisition of Jungla of $6.0 million which represents the hold-back obligation to issue 0.2 million shares subject to indemnification claims that may arise. This liability is adjusted at each reporting period based on the fair value of our common stock, which is a Level 3 input, with the change recorded in other income (expense), net. During July 2020, the hold-back shares were remitted in full to the former owners of Jungla. Clear Genetics In November 2019, we acquired 100% of the equity interest of Clear Genetics, a developer of software for providing genetic services at scale, for approximately $50.1 million . Of the cash and stock purchase price consideration issued, $0.2 million of cash and approximately 0.4 million shares of our common stock were subject to a 12-month hold back to satisfy indemnification obligations that may arise, 0.1 million of which were released during the three months ended June 30, 2020. As of June 30, 2020 , we had a stock payable liability related to our acquisition of Clear Genetics of $8.5 million which represents the hold-back obligation to issue 0.3 million shares subject to indemnification claims that may arise. This liability is adjusted at each reporting period based on the fair value of our common stock, which is a Level 3 input, with the change recorded in other income (expense), net. Diploid In March 2020, we acquired 100% of the equity interest of Diploid, a developer of artificial intelligence software capable of diagnosing genetic disorders using sequencing data and patient information, for approximately $82.3 million in cash and shares of our common stock. Of the stock purchase price consideration issued, approximately 0.4 million shares are subject to a hold-back to satisfy indemnification obligations that may arise. We included the financial results of Diploid in our consolidated financial statements from the acquisition date, which were not material for the six months ended June 30, 2020 . The following table summarizes the purchase price recorded as a part of the acquisition of Diploid (in thousands): Purchase Price Cash transferred $ 32,323 Hold-back consideration - common stock 7,538 Common stock transferred 42,453 Total $ 82,314 Assets acquired and liabilities assumed are recorded based on valuations derived from estimated fair value assessments and assumptions used by us. While we believe that our estimates and assumptions underlying the valuations are reasonable, different estimates and assumptions could result in different valuations assigned to the individual assets acquired and liabilities assumed, and the resulting amount of goodwill. The following table summarizes the fair values of assets acquired and liabilities assumed through our acquisition of Diploid at the date of acquisition (in thousands): Cash $ 124 Accounts receivable 26 Developed technology 41,789 Total identifiable assets acquired 41,939 Accounts payable (30 ) Deferred tax liability (10,250 ) Net identifiable assets acquired 31,659 Goodwill 50,655 Total purchase price $ 82,314 Based on the guidance provided in ASC 805, Business Combinations , we accounted for the acquisition of Diploid as a business combination in which we determined that 1) Diploid was a business which combines inputs and processes to create outputs, and 2) substantially all of the fair value of gross assets acquired was not concentrated in a single identifiable asset or group of similar identifiable assets. Our purchase price allocation for the acquisition is preliminary and subject to revision as additional information about fair value of assets and liabilities becomes available, primarily related to our deferred tax liability assumed in connection with the acquisition. Additional information that existed as of the acquisition date but at the time was unknown to us may become known to us during the remainder of the measurement period, a period not to exceed 12 months from the acquisition date. We measured the identifiable assets and liabilities assumed at their acquisition date fair values separately from goodwill. The intangible asset acquired is developed technology related to Diploid's artificial intelligence technology platform. The fair value of the developed technology was estimated using an income approach with an estimated useful life of nine years . As of the acquisition date, we recorded a stock payable liability of $7.5 million to represent the hold-back obligation to issue 0.4 million shares subject to indemnification claims that may arise. This liability is adjusted at each reporting period based on the fair value of our common stock, which is a Level 3 input. As of June 30, 2020 , the value of this liability was $12.8 million with the change recorded in other income (expense), net. Goodwill represents the excess of the purchase price over the fair value of the net tangible and intangible assets acquired. The acquisition of Diploid resulted in the recognition of $50.7 million of goodwill which we believe relates primarily to expansion of the acquired technology to apply to new areas of genetic testing. Goodwill created as a result of the acquisition of Diploid is not deductible for tax purposes. In June 2020, we granted 0.2 million RSUs with a fair value of $3.6 million under our 2015 Stock Incentive Plan as inducement awards in connection with our acquisition of Diploid. These RSUs vest in two equal installments, in April 2021 and April 2022. The value of the awards was recognized as research and development stock-based compensation upon grant in June 2020 as there were no ongoing obligations required by the award recipients. Genelex and YouScript In April 2020, we acquired 100% of the equity interest of Genelex and YouScript to bring pharmacogenetic testing and integrated clinical decision support to Invitae. We acquired Genelex for approximately $13.2 million , primarily in shares of our common stock. Of the stock purchase price consideration issued, approximately 0.1 million shares are subject to a hold-back to satisfy indemnification obligations that may arise. We acquired YouScript for approximately $52.7 million , including cash consideration of $24.5 million and the remaining in shares of our common stock. Of the purchase price consideration for YouScript, approximately $1.4 million and 0.5 million shares of our common stock are subject to a hold-back to satisfy indemnification obligations that may arise. We included the financial results of Genelex and YouScript in our consolidated financial statements from the acquisition date, which were not material for the six months ended June 30, 2020. We recorded $0.9 million of transaction costs related to the acquisition of Genelex and YouScript as general and administrative expense during the six months ended June 30, 2020. We may be required to pay contingent consideration in the form of additional shares of our common stock in connection with the acquisition of Genelex if, within a specified period following the closing, we achieve a certain product milestone, in which case we would issue shares of our common stock with a value equal to a portion of the gross revenues actually received by us for a pharmacogenetic product reimbursed through certain payers during an earn out period of up to four years . As of the acquisition date, the fair value of this contingent consideration was $2.0 million in the form of shares of our common stock. The material factors that may impact the fair value of the contingent consideration, and therefore, this liability, are the probabilities and timing of achieving the related milestone, the estimated revenues achieved for a pharmacogenetic product and the discount rate we used to estimate the fair value. Significant changes in any of the probabilities of success would result in a significant change in the fair value, which is estimated at each reporting date with changes reflected as general and administrative expense. As of June 30, 2020 , the fair value of the contingent consideration was $2.6 million . The following table summarizes the purchase prices recorded as a part of the acquisition of Genelex and YouScript (in thousands): Genelex YouScript Total Cash transferred $ 972 $ 24,462 $ 25,434 Hold-back consideration - cash — 1,385 1,385 Hold-back consideration - common stock 781 5,392 6,173 Contingent consideration 1,994 — 1,994 Common stock transferred 9,463 21,464 30,927 Total $ 13,210 $ 52,703 $ 65,913 Assets acquired and liabilities assumed are recorded based on valuations derived from estimated fair value assessments and assumptions used by us. While we believe that our estimates and assumptions underlying the valuations are reasonable, different estimates and assumptions could result in different valuations assigned to the individual assets acquired and liabilities assumed, and the resulting amount of goodwill. The following table summarizes the fair values of assets acquired and liabilities assumed through our acquisitions of Genelex and YouScript at the date of acquisition (in thousands): Genelex YouScript Total Cash $ 33 $ 24 $ 57 Accounts receivable 221 56 277 Prepaid expenses and other current assets — 70 70 Operating lease assets — 355 355 Developed technology 9,209 25,716 34,925 Total identifiable assets acquired 9,463 26,221 35,684 Current liabilities (320 ) (481 ) (801 ) Deferred tax liability — (2,600 ) (2,600 ) Other long-term liabilities — (163 ) (163 ) Net identifiable assets acquired 9,143 22,977 32,120 Goodwill 4,067 29,726 33,793 Total purchase price $ 13,210 $ 52,703 $ 65,913 Based on the guidance provided in ASC 805, Business Combinations , we accounted for the acquisitions of Genelex and YouScript as business combinations in which we determined that 1) Genelex and YouScript were businesses which combine inputs and processes to create outputs, and 2) substantially all of the fair value of gross assets acquired were not concentrated in a single identifiable asset or group of similar identifiable assets. Our purchase price allocation for the acquisitions is preliminary and subject to revision as additional information about fair value of assets and liabilities becomes available, primarily related to our deferred tax liability assumed. Additional information that existed as of the acquisition date but at the time was unknown to us may become known to us during the remainder of the measurement period, a period not to exceed 12 months from the acquisition date. We measured the identifiable assets and liabilities assumed at their acquisition date fair values separately from goodwill. The intangible assets acquired are the developed technologies related to Genelex's and YouScript's technology platforms. The fair value of the developed technologies were estimated using an income approach with an estimated useful life of eight years . As of the acquisition date, we recorded stock payable liabilities of $6.2 million to represent the hold-back obligation to issue shares subject to indemnification claims that may arise. These liabilities are adjusted at each reporting period based on the fair value of our common stock, which is a Level 3 input. As of June 30, 2020 , the value of this liability was $16.0 million with the change recorded in other income (expense), net. Goodwill represents the excess of the purchase price over the fair value of the net tangible and intangible assets acquired. The acquisitions of Genelex and YouScript resulted in the recognition of $33.8 million of goodwill which we believe relates primarily to future functionality and expansion of the acquired technologies. Of the goodwill recognized, $29.7 million related to the YouScript acquisition is not deductible for tax purposes. ArcherDX In June 2020, we entered into a definitive agreement with ArcherDX, a genomics analysis company democratizing precision oncology. Under the terms of the agreement, we will acquire ArcherDX for upfront consideration consisting of 30.0 million shares of Invitae common stock and $325.0 million in cash, plus up to an additional 27.0 million shares of Invitae common stock payable in connection with the achievement of certain milestones. The transaction is expected to close in several months from the signing of the definitive agreement, subject to customary closing conditions including approval by the stockholders of Invitae. In connection with the proposed transaction with ArcherDX, we have entered into a definitive agreement to sell $275.0 million in common stock in a private placement at a price of $16.85 per share. The private placement is expected to close concurrently with the proposed combination, subject to the satisfaction of customary closing conditions. The proceeds from the private placement are expected to be used to fund a portion of the cash consideration payable in the proposed merger with ArcherDX. In addition, we have entered into a debt commitment letter for up to a $200.0 million senior secured term loan facility, subject to completion of certain customary closing conditions. In connection with the credit facility, we will issue warrants to purchase 1.0 million shares of our common stock with an exercise price of $16.85

Goodwill and intangible assets

Goodwill and intangible assets	6 Months Ended
	Jun. 30, 2020
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill and intangible assets	Goodwill and intangible assets Goodwill The changes in the carrying amounts of goodwill were as follows (in thousands): Balance as of December 31, 2019 $ 126,777 Goodwill acquired - Diploid 50,655 Goodwill acquired - Genelex 4,067 Goodwill acquired - YouScript 29,726 Balance as of June 30, 2020 $ 211,225 Intangible assets The following table presents details of our intangible assets (in thousands): June 30, 2020 December 31, 2019 Cost Accumulated Net Weighted-Average Cost Accumulated Net Weighted-Average Customer relationships $ 23,763 $ (6,541 ) $ 17,222 10.0 $ 23,763 $ (5,141 ) $ 18,622 10.0 Developed technology 161,110 (16,188 ) 144,922 8.6 84,396 (8,476 ) 75,920 8.6 Non-compete agreement 286 (200 ) 86 5.0 286 (172 ) 114 5.0 Trade name 576 (559 ) 17 2.7 576 (480 ) 96 2.7 Patent licensing agreement 496 (87 ) 409 15.0 496 (70 ) 426 15.0 Favorable leases 247 (247 ) — 2.2 247 (238 ) 9 2.2 In-process research and development 29,988 — 29,988 n/a 29,988 — 29,988 n/a $ 216,466 $ (23,822 ) $ 192,644 8.8 $ 139,752 $ (14,577 ) $ 125,175 8.9 Acquisition-related intangibles included in the above table are finite-lived, other than in-process research and development which has an indefinite life, and are carried at cost less accumulated amortization. Customer relationships are being amortized on an accelerated basis, in proportion to estimated cash flows. All other finite-lived acquisition-related intangibles are being amortized on a straight-line basis over their estimated lives, which approximates the pattern in which the economic benefits of the intangible assets are realized. Amortization expense was $5.7 million and $1.3 million for the three months ended June 30, 2020 and 2019 , respectively, and $9.2 million and $2.6 million for the six months ended June 30, 2020 and 2019 , respectively. Amortization expense is recorded to cost of revenue, research and development, sales and marketing and general and administrative expense. The following table summarizes our estimated future amortization expense of intangible assets with finite lives as of June 30, 2020 (in thousands): 2020 (remainder of year) $ 11,207 2021 22,793 2022 21,087 2023 20,074 2024 19,796 Thereafter 67,699 Total estimated future amortization expense $ 162,656

Balance sheet components

Balance sheet components	6 Months Ended
	Jun. 30, 2020
Balance Sheet Related Disclosures [Abstract]
Balance sheet components	Balance sheet components Property and equipment, net Property and equipment consisted of the following (in thousands): June 30, 2020 December 31, 2019 Leasehold improvements $ 23,251 $ 18,352 Laboratory equipment 30,668 24,873 Computer equipment 6,760 5,995 Software 2,611 2,611 Furniture and fixtures 1,277 1,198 Automobiles 58 58 Construction-in-progress 9,070 10,795 Total property and equipment, gross 73,695 63,882 Accumulated depreciation and amortization (30,314 ) (26,135 ) Total property and equipment, net $ 43,381 $ 37,747 Depreciation expense was $2.3 million and $1.8 million for the three months ended June 30, 2020 and 2019 , respectively, and $4.4 million and $3.4 million for the six months ended June 30, 2020 and 2019 , respectively. Accrued liabilities Accrued liabilities consisted of the following (in thousands): June 30, 2020 December 31, 2019 Accrued compensation and related expenses $ 20,144 $ 16,440 Compensation and other liabilities associated with business combinations 64,976 30,560 Deferred revenue 1,726 1,429 Other 12,644 16,385 Total accrued liabilities $ 99,490 $ 64,814

Fair value measurements

Fair value measurements	6 Months Ended
	Jun. 30, 2020
Fair Value Disclosures [Abstract]
Fair value measurements	Fair value measurements Financial assets and liabilities are recorded at fair value. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (an exit price) in an orderly transaction between market participants at the reporting date. The authoritative guidance establishes a three-level valuation hierarchy that prioritizes the inputs to valuation techniques used to measure fair value based upon whether such inputs are observable or unobservable. Observable inputs reflect market data obtained from independent sources, while unobservable inputs reflect market assumptions made by the reporting entity. The three-level hierarchy for the inputs to valuation techniques is summarized as follows: Level 1—Observable inputs such as quoted prices (unadjusted) for identical instruments in active markets. Level 2—Observable inputs such as quoted prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active, or model-derived valuations whose significant inputs are observable. Level 3—Unobservable inputs that reflect the reporting entity’s own assumptions. The following tables set forth the fair value of our consolidated financial instruments that were measured at fair value on a recurring basis (in thousands): June 30, 2020 Amortized Cost Unrealized Estimated Fair Value Gains Losses Level 1 Level 2 Level 3 Financial assets: Money market funds $ 132,990 $ — $ — $ 132,990 $ 132,990 $ — $ — Certificates of deposit 300 — — 300 — 300 — U.S. treasury notes 197,721 570 — 198,291 198,291 — — U.S. government agency securities 55,340 2 — 55,342 — 55,342 — Total financial assets $ 386,351 $ 572 $ — $ 386,923 $ 331,281 $ 55,642 $ — Financial liabilities: Stock payable liability $ 43,625 $ — $ — $ 43,625 Contingent consideration 18,018 — — 18,018 Total financial liabilities $ 61,643 $ — $ — $ 61,643 June 30, 2020 Reported as: Cash equivalents $ 126,647 Restricted cash 6,343 Marketable securities 253,933 Total cash equivalents, restricted cash, and marketable securities $ 386,923 Accrued liabilities $ 15,441 Other long-term liabilities $ 46,202 December 31, 2019 Amortized Cost Unrealized Estimated Fair Value Gains Losses Level 1 Level 2 Level 3 Financial assets: Money market funds $ 39,396 $ — $ — $ 39,396 $ 39,396 $ — $ — Certificates of deposit 300 — — 300 — 300 — U.S. treasury notes 150,627 — (15 ) 150,612 150,612 — — U.S. government agency securities 193,302 6 — 193,308 — 193,308 — Total financial assets $ 383,625 $ 6 $ (15 ) $ 383,616 $ 190,008 $ 193,608 $ — Financial liabilities: Contingent consideration $ 11,300 — — $ 11,300 Total financial liabilities $ 11,300 — — $ 11,300 December 31, 2019 Reported as: Cash equivalents $ 136,997 Restricted cash 6,183 Marketable securities 240,436 Total cash equivalents, restricted cash, and marketable securities $ 383,616 Accrued liabilities $ 3,300 Other long-term liabilities $ 8,000 There were no transfers between Level 1, Level 2 and Level 3 during the periods presented. The total fair value of investments with unrealized losses at June 30, 2020 was $80.2 million . None of the available-for-sale securities held as of June 30, 2020 have been in a continuous unrealized loss position for more than one year. Our certificates of deposit and debt securities of U.S. government agency entities are classified as Level 2 as they are valued based upon quoted market prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active and model-based valuation techniques for which all significant inputs are observable in the market or can be corroborated by observable market data for substantially the full term of the assets. Where applicable, these models project future cash flows and discount the future amounts to a present value using market-based observable inputs obtained from various third-party data providers, including but not limited to benchmark yields, interest rate curves, reported trades, broker/dealer quotes and reference data. Stock payable liabilities relate to certain indemnification hold-backs resulting from business combinations that are settled in shares of our common stock. We elected to account for these liabilities using the fair value option due to the inherent nature of the liabilities and the changes in value of the underlying shares that will ultimately be issued to settle the liabilities. The estimated fair value of these liabilities is classified as Level 3 and determined based upon the number of shares that are issuable to the sellers and the quoted closing price of our common stock as of the reporting date. The number of shares that will ultimately be issued is subject to adjustment for indemnified claims that existed as of the closing date for each acquisition. Changes in the number of shares issued and share price can significantly affect the estimated fair value of the liabilities. During the three and six months ended June 30, 2020 , the change in fair value related to stock payable liabilities recorded to other income (expense), net was expense of $25.4 million and $21.7 million , respectively. As of June 30, 2020 , we had contingent obligations of $15.4 million of our common stock to the former owners of Jungla in connection with our acquisition of Jungla in July 2019. The amount of the contingent obligation is dependent upon achievement of certain post-close development milestones. We estimated the fair value of the contingent consideration as $10.7 million at the acquisition date in July 2019 using a discounted cash flow technique based on estimated achievement of the post-close milestones and discount rates which were Level 3 inputs not supported by market activity. These inputs can significantly affect the estimated fair value of the contingent consideration. The value of the liability is subsequently remeasured to fair value at each reporting date with changes recorded as general and administrative expense. As of June 30, 2020 , we had contingent obligations of $2.6 million of our common stock to the former owners of Genelex in connection with our acquisition of Genelex in April 2020. The amount of the contingent obligation is dependent upon achievement of a certain post-close milestone and the gross revenues actually received by us for a pharmacogenetic product reimbursed through certain payers during an earn out period of up to four years. We estimated the fair value of the contingent consideration as $2.0 million at the acquisition date in April 2020 using a discounted cash flow technique based on estimated achievement of the post-close milestone, our estimate of amounts to ultimately be paid, and discount rates which were Level 3 inputs not supported by market activity. These inputs can significantly affect the estimated fair value of the contingent consideration. The value of the liability is subsequently remeasured to fair value at each reporting date with changes recorded as general and administrative expense.

Commitments and contingencies

Commitments and contingencies	6 Months Ended
	Jun. 30, 2020
Commitments and Contingencies Disclosure [Abstract]
Commitments and contingencies	Commitments and contingencies Leases Operating leases In 2015, we entered into a lease agreement for our headquarters and main production facility in San Francisco, California which commenced in 2016. This lease expires in 2026 and we may renew the lease for an additional ten years . This optional period was not considered reasonably certain to be exercised and therefore we determined the lease term to be a ten -year period expiring in 2026. In connection with the execution of the lease, we provided a security deposit of approximately $4.6 million which is included in restricted cash in our consolidated balance sheets. We also have other operating leases for office and laboratory space in California, Massachusetts, New York and Washington. We expect to enter into new leases and modifying existing leases as we support continued growth of our operations. As of June 30, 2020 , the weighted-average remaining lease term for our operating leases was 5.9 years and the weighted-average discount rate used to determine our operating lease liability was 11.5% . Cash payments included in the measurement of our operating lease liabilities were $2.7 million and $2.5 million for the three months ended June 30, 2020 and 2019 , respectively, and $5.4 million and $4.9 million for the six months ended June 30, 2020 and 2019 , respectively. The components of lease costs, which were included in cost of revenue, research and development, selling and marketing and general and administrative expenses on our consolidated statements of operations were as follows (in thousands): Three Months Ended June 30, Six Months Ended June 30, 2020 2019 2020 2019 Operating lease costs $ 2,653 $ 2,564 $ 5,268 $ 5,081 Sublease income — (43 ) — (86 ) Total operating lease costs 2,653 2,521 5,268 4,995 Finance lease costs 475 391 959 811 Total lease costs $ 3,128 $ 2,912 $ 6,227 $ 5,806 Future minimum payments under non-cancelable operating leases as of June 30, 2020 are as follows (in thousands): 2020 (remainder of year) $ 5,749 2021 11,693 2022 10,922 2023 10,424 2024 10,560 Thereafter 18,459 Future non-cancelable minimum operating lease payments 67,807 Less: imputed interest (19,334 ) Total operating lease liabilities 48,473 Less: current portion (6,339 ) Operating lease obligations, net of current portion $ 42,134 Finance leases We have entered into various finance lease agreements to obtain laboratory equipment. The terms of our finance leases are generally three years with a weighted-average remaining lease term of 2.0 years as of June 30, 2020 and are typically secured by the underlying equipment. The weighted-average discount rate used to determine our finance lease liability was 5.6% . The portion of the future payments designated as principal repayment was classified as a finance lease obligation on our consolidated balance sheets. Finance lease assets are recorded within other assets on our consolidated balance sheet and were $4.7 million and $5.6 million as of June 30, 2020 and December 31, 2019 , respectively. Cash payments included in the measurement of our finance lease liabilities were $0.6 million for each of the three months periods ended June 30, 2020 and 2019 , and $1.3 million and $1.1 million for the six months ended June 30, 2020 and 2019 , respectively. Future payments under finance leases at June 30, 2020 are as follows (in thousands): 2020 (remainder of year) $ 741 2021 611 2022 612 Total finance lease obligations 1,964 Less: interest (108 ) Present value of net minimum finance lease payments 1,856 Less: current portion (977 ) Finance lease obligations, net of current portion $ 879 Debt financing In November 2018, we entered into a Note Purchase Agreement (the "2018 Note Purchase Agreement") pursuant to which we were eligible to borrow an aggregate principal amount up to $200.0 million over a seven year maturity term which included an initial borrowing of $75.0 million in November 2018. We received net proceeds of $10.3 million after terminating and repaying the balance of our obligations of approximately $64.7 million with our previous lender. In September 2019, we settled our obligations under the 2018 Note Purchase Agreement in full for $85.7 million , which included repayment of principal of $75.0 million , accrued interest of $2.4 million , and prepayment fees of $8.9 million which were recorded as debt extinguishment costs in other income (expense), net in our statement of operations during the three months ended September 30, 2019. Interest expense related to our debt financings, excluding the impact of our Convertible Senior Notes (defined below), was nil and $2.0 million for the three months ended June 30, 2020 and 2019 , respectively, and nil and $3.9 million for the six months ended June 30, 2020 and 2019 , respectively. Convertible Senior Notes In September 2019, we issued, at par value, $350.0 million aggregate principal amount of 2.00% Convertible Senior Notes due 2024 ("Convertible Senior Notes") in a private offering. The Convertible Senior Notes are our senior unsecured obligations and will mature on September 1, 2024, unless earlier converted, redeemed or repurchased. The Convertible Senior Notes bear cash interest at a rate of 2.0% per year, payable semi-annually in arrears on March 1 and September 1 of each year, beginning on March 1, 2020. Upon conversion, the Convertible Senior Notes will be convertible into cash, shares of our common stock or a combination of cash and shares of our common stock, at our election. Our current intent is to settle the principal amount of the Convertible Senior Notes in cash upon conversion, with any remaining conversion value being delivered in shares of our common stock. The initial conversion rate for the Convertible Senior Notes is 33.6293 shares of our common stock per $1,000 principal amount of the Convertible Senior Notes (equivalent to an initial conversion price of approximately $29.74 per share of common stock). If we undergo a fundamental change (as defined in the indenture governing the Convertible Senior Notes), the holders of the Convertible Senior Notes may require us to repurchase all or any portion of their Convertible Senior Notes for cash at a repurchase price equal to 100% of the principal amount of the Convertible Senior Notes to be repurchased plus accrued and unpaid interest to, but excluding, the redemption date. The Convertible Senior Notes will be convertible at the option of the holders at any time prior to the close of business on the business day immediately preceding March 1, 2024, only under the following circumstances: (1) during any calendar quarter commencing after the calendar quarter ending on December 31, 2019 (and only during such calendar quarter), if the last reported sale price of our common stock for at least 20 trading days (whether or not consecutive) during a period of 30 consecutive trading days ending on, and including, the last trading day of the immediately preceding calendar quarter is greater than or equal to 130% of the conversion price for the Convertible Senior Notes on each applicable trading day; (2) during the five business day period after any five consecutive trading day period (the “measurement period”) in which the trading price per $1,000 principal amount of Convertible Senior Notes for each trading day of the measurement period was less than 98% of the product of the last reported sale price of our common stock and the conversion rate on each such trading day; (3) if we call any or all of the Convertible Senior Notes for redemption, at any time prior to the close of business on the scheduled trading day immediately preceding the redemption date; or (4) upon the occurrence of specified corporate events. On or after March 1, 2024 until the close of business on the business day immediately preceding the maturity date, holders may convert their Convertible Senior Notes at any time, regardless of the foregoing circumstances. As of June 30, 2020 , none of the above circumstances had occurred and therefore the Convertible Senior Notes could not have been converted. We may not redeem the Convertible Senior Notes prior to September 6, 2022. We may redeem for cash all or any portion of the Convertible Senior Notes, at our option, on or after September 6, 2022 and on or before the 30 th scheduled trading day immediately before the maturity date if the last reported sale price of the Common Stock has been at least 130% of the conversion price then in effect for at least 20 trading days (whether or not consecutive) during any 30 consecutive trading day period (including the last trading day of such period) ending on, and including, the trading day immediately preceding the date on which we provide notice of redemption at a redemption price equal to 100% of the principal amount of the notes to be redeemed, plus accrued and unpaid interest to, but excluding, the redemption date. The Convertible Senior Notes as of June 30, 2020 consisted of the following (in thousands): Outstanding principal $ 350,000 Unamortized debt discount and issuance costs (73,908 ) Net carrying amount, liability component $ 276,092 As of June 30, 2020 , the fair value of the Convertible Senior Notes was $406.9 million . The estimated fair value of the Convertible Senior Notes, which are classified as Level 2 financial instruments, was determined based on the estimated or actual bid prices of the Convertible Senior Notes in an over-the-counter market. We recognized $5.5 million and $10.9 million of interest expense related to the Convertible Senior Notes during the three and six months ended June 30, 2020 , respectively. Other commitments In the normal course of business, we enter into various purchase commitments primarily related to service agreements and laboratory supplies. At June 30, 2020 , our total future payments under noncancelable unconditional purchase commitments having a remaining term of over one year were $6.0 million . Guarantees and indemnifications As permitted under Delaware law and in accordance with our bylaws, we indemnify our directors and officers for certain events or occurrences while the officer or director is or was serving in such capacity. The maximum amount of potential future indemnification is unlimited; however, we maintain director and officer liability insurance. This insurance allows the transfer of the risk associated with our exposure and may enable us to recover a portion of any future amounts paid. We believe the fair value of these indemnification agreements is minimal. Accordingly, we did not record any liabilities associated with these indemnification agreements at June 30, 2020 or December 31, 2019 . Contingencies We were not a party to any material legal proceedings at June 30, 2020 , or at the date of this report. We are and may from time to time become involved in various legal proceedings and claims arising in the ordinary course of business. While we believe any such claims are unsubstantiated, and we believe we are in compliance with applicable laws and regulations applicable to our business, the resolution of any such claims could be material.

Stockholders' equity

Stockholders' equity	6 Months Ended
	Jun. 30, 2020
Equity [Abstract]
Stockholders' equity	Stockholders’ equity Shares outstanding Shares of convertible preferred and common stock were as follows (in thousands): Three Months Ended June 30, Six Months Ended June 30, 2020 2019 2020 2019 Convertible preferred stock: Shares outstanding, beginning of period 125 125 125 3,459 Conversion into common stock — — — (3,334 ) Shares outstanding, end of period 125 125 125 125 Common stock: Shares outstanding, beginning of period 101,920 89,601 98,796 75,481 Common stock issued in connection with public offering 23,058 — 23,058 10,350 Common stock issued on exercise of stock options, net 130 80 308 340 Common stock issued pursuant to vesting of RSUs 3,055 1,124 3,481 1,245 Common stock issued pursuant to exercises of warrants 6 4 148 19 Common stock issued pursuant to employee stock purchase plan 342 235 342 235 Common stock issued pursuant to business combinations 2,778 2,719 5,156 2,759 Common stock issued upon conversion of preferred stock — — — 3,334 Shares outstanding, end of period 131,289 93,763 131,289 93,763 2018 Sales Agreement In August 2018, we entered into a Common Stock Sales Agreement (the “2018 Sales Agreement”) with Cowen and Company, LLC (“Cowen”), under which we may offer and sell from time to time at our sole discretion shares of our common stock through Cowen as our sales agent, in an aggregate amount not to exceed $75.0 million . Cowen may sell the shares by any method permitted by law deemed to be an “at the market” offering as defined in Rule 415 of the Securities Act of 1933, including without limitation sales made directly on The New York Stock Exchange, and also may sell the shares in privately negotiated transactions, subject to our prior approval. Per the terms of the agreement, Cowen receives a commission equal to 3% of the gross proceeds of the sales price of all shares sold through it as sales agent under the 2018 Sales Agreement. In March 2019, we amended the 2018 Sales Agreement to increase the aggregate amount of our common stock to be sold under this agreement not to exceed $175.0 million . During the second quarter of 2020, we sold a total of 2.6 million shares of common stock under the 2018 Sales Agreement at an average price of $17.60 per share for aggregate gross proceeds of $46.0 million and net proceeds of $44.5 million . Pursuant to the Securities Purchase Agreement in connection with the private placement, we have agreed not to use the 2018 Sales Agreement unless certain conditions are met. Public offering In April 2020, we sold, in an underwritten public offering, an aggregate of 20.4 million shares of our common stock at a price of $9.00 per share, for gross proceeds of $184.0 million and net proceeds of $173.0 million after deducting underwriting discounts and commissions and offering expenses.

Stock incentive plans

Stock incentive plans	6 Months Ended
	Jun. 30, 2020
Share-based Payment Arrangement [Abstract]
Stock incentive plans	Stock incentive plans Stock incentive plans In 2010, we adopted the 2010 Incentive Plan (the “2010 Plan”). The 2010 Plan provides for the granting of stock-based awards to employees, directors and consultants under terms and provisions established by our Board of Directors. Under the terms of the 2010 Plan, options may be granted at an exercise price not less than the fair market value of our common stock. For employees holding more than 10% of the voting rights of all classes of stock, the exercise prices for incentive and nonstatutory stock options must be at least 110% of fair market of our common stock on the grant date, as determined by our Board of Directors. The terms of options granted under the 2010 Plan may not exceed ten years . In January 2015, we adopted the 2015 Stock Incentive Plan (the “2015 Plan”), which became effective upon the closing of our initial public offering (“IPO”). Shares outstanding under the 2010 Plan were transferred to the 2015 Plan upon effectiveness of the 2015 Plan. The 2015 Plan provides for automatic annual increases in shares available for grant, beginning on January 1, 2016 through January 1, 2025. In addition, shares subject to awards under the 2010 Plan that are forfeited or terminated will be added to the 2015 Plan. The 2015 Plan provides for the grant of incentive stock options, nonstatutory stock options, restricted stock awards, stock units, stock appreciation rights and other forms of equity compensation, all of which may be granted to employees, including officers, non-employee directors and consultants. Additionally, the 2015 Plan provides for the grant of cash-based awards. We amended and restated the 2015 Plan to create a pool of shares to be awarded solely as a material inducement to employees. Options granted generally vest over a period of four years . Typically, the vesting schedule for options granted to newly hired employees provides that 1/4 of the award vests upon the first anniversary of the employee’s date of hire, with the remainder of the award vesting monthly thereafter at a rate of 1/48 of the total shares subject to the option. All other options typically vest in equal monthly installments over the four-year vesting schedule. RSUs generally vest over a period of three years . Typically, the vesting schedule for RSUs provides that 1/3 of the award vests upon each anniversary of the grant date, with certain awards that include a portion that vests immediately upon grant. In June 2019, we granted Time-based RSUs in connection with the acquisition of Singular Bio which vest in three equal installments over a period of 18 months and PRSUs that vest based on the achievement of performance conditions; see further details in Note 4, "Business combinations." Under our management incentive compensation plan, in July 2019 we granted PRSUs to our executive officers as well as other specified senior level employees based on the level of achievement of a specified 2019 revenue goal. One-third of the 0.8 million shares that were ultimately awarded under this plan vested during the six months ended June 30, 2020 and the remaining awards will continue to vest over a period of two years . In June 2020, we granted 0.3 million PRSUs under this plan which are based on the level of achievement of a specified 2020 cash burn goal. These PRSUs will vest beginning in 2021 over a period of one year and may range from 0% to 100% of the target amount of shares, depending on eligibility and performance. As of June 30, 2020 , these PRSUs had a fair value of $3.6 million based on an estimated issuance of 0.2 million shares and expectation of the performance condition. Activity under the 2010 Plan and the 2015 Plan is set forth below (in thousands, except per share amounts and years): Shares Available For Grant Stock Options Outstanding Weighted-Average Exercise Price Per Share Weighted-Average Remaining Contractual Life (Years) Aggregate Intrinsic Value Balances at December 31, 2019 5,444 3,542 $ 9.49 6.1 $ 24,966 Additional shares reserved 5,027 — Options granted (282 ) 282 16.28 Options exercised — (308 ) 7.04 RSUs and PRSUs granted (1) (3,150 ) — RSUs and PRSUs cancelled 337 — Balances at June 30, 2020 7,376 3,516 $ 10.26 6.1 $ 70,414 Options exercisable at June 30, 2020 2,940 $ 9.30 5.5 $ 61,695 Options vested and expected to vest at June 30, 2020 3,414 $ 10.08 6.0 $ 68,992 (1) Includes the changes in the Time-based RSUs and PRSUs granted as a part of the Singular Bio acquisition in June 2019 which are based on a fixed dollar value. The number of shares issued will be variable until the awards vest. See further details in Note 4, "Business combinations." The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying stock options and the fair value of our common stock for stock options that were in-the-money. The weighted-average fair value per share of options to purchase common stock granted was $10.10 and $14.52 in the six months ended June 30, 2020 and 2019, respectively. The total grant-date fair value of options to purchase common stock vested was $1.8 million and $2.5 million in the six months ended June 30, 2020 and 2019 , respectively. The intrinsic value of options to purchase common stock exercised was $3.7 million and $4.5 million in the six months ended June 30, 2020 and 2019 , respectively. The following table summarizes RSU activity, which includes the changes in Time-based RSUs and PRSUs granted in connection with our acquisition of Singular Bio (in thousands, except per share data): Number of Shares Weighted- Average Grant Date Fair Value Per Share Balance at December 31, 2019 8,885 $ 15.17 RSUs granted 3,739 $ 15.35 Time-based RSUs and PRSUs granted - Singular Bio (1) (863 ) $ 23.58 PRSUs granted 274 $ 16.17 RSUs vested (3,481 ) $ 15.32 RSUs cancelled (337 ) $ 18.83 Balance at June 30, 2020 8,217 $ 14.19 (1) Includes the changes in the Time-based RSUs and PRSUs granted as a part of the Singular Bio acquisition in June 2019 which are based on a fixed dollar value. The number of shares issued will be variable until the awards vest which are adjusted above. The weighted-average grant date fair value per share reflects the fair value pricing of the full award. See further details in Note 4, "Business combinations." 2015 Employee Stock Purchase Plan In January 2015, we adopted the 2015 Employee Stock Purchase Plan (the “ESPP”), which became effective upon the closing of the IPO. Employees participating in the ESPP may purchase common stock at 85% of the lesser of the fair market value of common stock on the purchase date or last trading day preceding the offering date. At June 30, 2020 , cash received from payroll deductions pursuant to the ESPP was $1.0 million . At June 30, 2020 , a total of 1.2 million shares of common stock were reserved for issuance under the ESPP. Stock-based compensation The following table summarizes stock-based compensation expense included in the consolidated statements of operations (in thousands): Three Months Ended June 30, Six Months Ended June 30, 2020 2019 2020 2019 Cost of revenue $ 2,356 $ 2,205 $ 3,217 $ 2,856 Research and development 41,565 6,767 63,769 8,572 Selling and marketing 3,298 2,914 5,120 4,157 General and administrative 4,627 2,431 9,018 3,955 Total stock-based compensation expense $ 51,846 $ 14,317 $ 81,124 $ 19,540

Net loss per share

Net loss per share	6 Months Ended
	Jun. 30, 2020
Earnings Per Share [Abstract]
Net loss per share	Net loss per share The following table presents the calculation of basic and diluted net loss per share (in thousands, except per share amounts): Three Months Ended June 30, Six Months Ended June 30, 2020 2019 2020 2019 Net loss $ (166,403 ) $ (48,676 ) $ (264,930 ) $ (86,353 ) Shares used in computing net loss per share, basic and diluted 129,023 90,863 112,765 85,148 Net loss per share, basic and diluted $ (1.29 ) $ (0.54 ) $ (2.35 ) $ (1.01 ) The following common stock equivalents have been excluded from diluted net loss per share because their inclusion would be anti-dilutive (in thousands): Three Months Ended June 30, Six Months Ended June 30, 2020 2019 2020 2019 Shares of common stock subject to outstanding options 3,416 3,669 3,447 3,714 Shares of common stock subject to outstanding warrants 369 593 429 601 Shares of common stock subject to outstanding RSUs 6,403 4,569 5,716 4,350 Shares of common stock subject to outstanding PRSUs 2,379 — 2,586 — Shares of common stock pursuant to ESPP 313 46 318 55 Shares of common stock underlying Series A convertible preferred stock 125 125 125 1,288 Shares of common stock subject to convertible senior notes exercise 11,555 — 11,555 — Total shares of common stock equivalents 24,560 9,002 24,176 10,008

Geographic information

Geographic information	6 Months Ended
	Jun. 30, 2020
Segments, Geographical Areas [Abstract]
Geographic information	Geographic information Revenue by country is determined based on the billing address of the customer. The following presents revenue by country (in thousands): Three Months Ended June 30, Six Months Ended June 30, 2020 2019 2020 2019 United States $ 43,334 $ 50,368 $ 103,140 $ 88,013 Canada 797 882 2,016 1,847 Rest of world 2,060 2,225 5,283 4,168 Total revenue $ 46,191 $ 53,475 $ 110,439 $ 94,028

Subsequent events

Subsequent events	6 Months Ended
	Jun. 30, 2020
Subsequent Events [Abstract]
Subsequent events	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;background-color:#ffff00;font-weight:bold;">Subsequent events</font></div></div>

Summary of significant accoun_2

Summary of significant accounting policies (Policies)	6 Months Ended
	Jun. 30, 2020
Accounting Policies [Abstract]
Basis of presentation	Basis of presentation The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”) for interim financial information and in accordance with the instructions to Form 10-Q and Rule 10-01 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements. The unaudited interim condensed consolidated financial statements have been prepared on the same basis as the annual financial statements. In the opinion of management, the accompanying unaudited condensed consolidated financial statements reflect all adjustments (consisting only of normal recurring adjustments) considered necessary for a fair presentation. The information included in this Quarterly Report on Form 10-Q should be read in conjunction with the audited financial statements and notes thereto included in our Annual Report on Form 10-K for the year ended December 31, 2019 . The results for the three and six months ended June 30, 2020 are not necessarily indicative of the results expected for the full fiscal year or any other periods.
Principles of consolidation	Principles of consolidation Our unaudited condensed consolidated financial statements include our accounts and the accounts of our wholly-owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation.
Use of estimates	Use of estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make judgments, estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities as of the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. We base these estimates on current facts, historical and anticipated results, trends and various other assumptions that we believe are reasonable under the circumstances, including assumptions as to future events. Actual results could differ materially from those judgments, estimates and assumptions. We evaluate our estimates on an ongoing basis.
Concentrations of credit risk and other risks and uncertainties	Concentrations of credit risk and other risks and uncertainties Financial instruments that potentially subject us to a concentration of credit risk consist of cash, cash equivalents, marketable securities and accounts receivable. Our cash and cash equivalents are held by financial institutions in the United States. Such deposits may exceed federally insured limits.
Inventory	Inventory
Fair value of financial instruments	Fair value of financial instruments Our financial instruments consist principally of cash and cash equivalents, marketable securities, accounts payable, accrued liabilities, finance leases and liabilities associated with business combinations. The carrying amounts of certain of these financial instruments, including cash and cash equivalents, accounts receivable, accounts payable and accrued and other current liabilities approximate their current fair value due to the relatively short-term nature of these accounts. Based on borrowing rates available to us, the carrying value of our finance leases approximate their fair values. Liabilities associated with business combinations are recorded at their estimated fair value.
Prior period reclassifications	Prior period reclassifications We have reclassified certain amounts in prior periods to conform with current presentation.
Recent accounting pronouncements	Recent accounting pronouncements We evaluate all Accounting Standards Updates (“ASUs”) issued by the Financial Accounting Standards Board ("FASB") for consideration of their applicability. ASUs not included in the disclosures in this report were assessed and determined to be either not applicable or are not expected to have a material impact on our consolidated financial statements. Recently adopted accounting pronouncements In June 2016, FASB issued ASU 2016-13, Financial Instruments-Credit Losses (Topic 326), which requires measurement and recognition of expected credit losses for financial assets. This guidance became effective for us beginning in the first quarter of 2020 and was adopted using a modified retrospective approach, with certain exceptions. The adoption of Topic 326 did not have a material impact on our consolidated financial statements as credit losses are not expected to be significant. As part of our adoption of Topic 326, we assess our accounts receivables for expected credit losses at each reporting period by disaggregating by payer type and further by portfolios of customers with similar characteristics, such as customer type and geographic location. We then review each portfolio for expected credit losses based on historical payment trends as well as forward looking data and current economic trends. If a credit loss is determined, we record a reduction to our accounts receivable balance with a corresponding general and administrative expense.

Summary of significant accoun_3

Summary of significant accounting policies (Tables)	6 Months Ended
	Jun. 30, 2020
Accounting Policies [Abstract]
Summary of significant customers as percentage of total revenue and total accounts receivable	Our revenue from significant customers as a percentage of our total revenue was as follows: Three Months Ended June 30, Six Months Ended June 30, 2020 2019 2020 2019 Medicare 20 % 23 % 21 % 22 % United Healthcare * 10 % * 10 % * Balance represents less than 10% of total revenue
Summary of restrictions on cash and cash equivalents	The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the consolidated balance sheets that sum to the total of the same amounts shown in the statements of cash flows (in thousands): June 30, December 31, Cash and cash equivalents $ 168,203 $ 151,389 Restricted cash 6,343 6,183 Total cash, cash equivalents and restricted cash $ 174,546 $ 157,572
Schedule of cash and cash equivalents	The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the consolidated balance sheets that sum to the total of the same amounts shown in the statements of cash flows (in thousands): June 30, December 31, Cash and cash equivalents $ 168,203 $ 151,389 Restricted cash 6,343 6,183 Total cash, cash equivalents and restricted cash $ 174,546 $ 157,572

Revenue, accounts receivable _2

Revenue, accounts receivable and deferred revenue (Tables)	6 Months Ended
	Jun. 30, 2020
Revenue from Contract with Customer [Abstract]
Schedule of disaggregated revenue by payer category	The following table includes our revenues as disaggregated by payer category (in thousands): Three Months Ended June 30, Six Months Ended June 30, 2020 2019 2020 2019 Test revenue: Institutions $ 9,531 $ 9,814 $ 23,028 $ 17,968 Patient - direct 4,298 4,056 10,089 7,797 Patient - insurance 31,270 38,432 75,060 66,156 Total test revenue 45,099 52,302 108,177 91,921 Other revenue 1,092 1,173 2,262 2,107 Total revenue $ 46,191 $ 53,475 $ 110,439 $ 94,028
Schedule of change in estimate	As a result of new information, we updated our estimate of the amounts to be recognized for previously delivered tests which resulted in the following increases to revenue and decreases to our loss from operations and basic and diluted net loss per share (in millions, except per share amounts): Three Months Ended June 30, Six Months Ended June 30, 2020 2019 2020 2019 Revenue $ 0.9 $ 2.4 $ 2.3 $ 2.8 Loss from operations $ (0.9 ) $ (2.4 ) $ (2.3 ) $ (2.8 ) Net loss per share, basic and diluted $ (0.01 ) $ (0.03 ) $ (0.02 ) $ (0.03 )

Business combinations (Tables)

Business combinations (Tables)	6 Months Ended
	Jun. 30, 2020
Business Combinations [Abstract]
Summary of purchase price and post-combination expense	The following table summarizes the purchase price recorded as a part of the acquisition of Diploid (in thousands): Purchase Price Cash transferred $ 32,323 Hold-back consideration - common stock 7,538 Common stock transferred 42,453 Total $ 82,314 The following table summarizes the purchase prices recorded as a part of the acquisition of Genelex and YouScript (in thousands): Genelex YouScript Total Cash transferred $ 972 $ 24,462 $ 25,434 Hold-back consideration - cash — 1,385 1,385 Hold-back consideration - common stock 781 5,392 6,173 Contingent consideration 1,994 — 1,994 Common stock transferred 9,463 21,464 30,927 Total $ 13,210 $ 52,703 $ 65,913
Summary of fair values of assets acquired and liabilities assumed	The following table summarizes the fair values of assets acquired and liabilities assumed through our acquisition of Diploid at the date of acquisition (in thousands): Cash $ 124 Accounts receivable 26 Developed technology 41,789 Total identifiable assets acquired 41,939 Accounts payable (30 ) Deferred tax liability (10,250 ) Net identifiable assets acquired 31,659 Goodwill 50,655 Total purchase price $ 82,314 Genelex YouScript Total Cash $ 33 $ 24 $ 57 Accounts receivable 221 56 277 Prepaid expenses and other current assets — 70 70 Operating lease assets — 355 355 Developed technology 9,209 25,716 34,925 Total identifiable assets acquired 9,463 26,221 35,684 Current liabilities (320 ) (481 ) (801 ) Deferred tax liability — (2,600 ) (2,600 ) Other long-term liabilities — (163 ) (163 ) Net identifiable assets acquired 9,143 22,977 32,120 Goodwill 4,067 29,726 33,793 Total purchase price $ 13,210 $ 52,703 $ 65,913

Goodwill and intangible assets

Goodwill and intangible assets (Tables)	6 Months Ended
	Jun. 30, 2020
Goodwill and Intangible Assets Disclosure [Abstract]
Summary of goodwill	The changes in the carrying amounts of goodwill were as follows (in thousands): Balance as of December 31, 2019 $ 126,777 Goodwill acquired - Diploid 50,655 Goodwill acquired - Genelex 4,067 Goodwill acquired - YouScript 29,726 Balance as of June 30, 2020 $ 211,225
Schedule of intangible assets	The following table presents details of our intangible assets (in thousands): June 30, 2020 December 31, 2019 Cost Accumulated Net Weighted-Average Cost Accumulated Net Weighted-Average Customer relationships $ 23,763 $ (6,541 ) $ 17,222 10.0 $ 23,763 $ (5,141 ) $ 18,622 10.0 Developed technology 161,110 (16,188 ) 144,922 8.6 84,396 (8,476 ) 75,920 8.6 Non-compete agreement 286 (200 ) 86 5.0 286 (172 ) 114 5.0 Trade name 576 (559 ) 17 2.7 576 (480 ) 96 2.7 Patent licensing agreement 496 (87 ) 409 15.0 496 (70 ) 426 15.0 Favorable leases 247 (247 ) — 2.2 247 (238 ) 9 2.2 In-process research and development 29,988 — 29,988 n/a 29,988 — 29,988 n/a $ 216,466 $ (23,822 ) $ 192,644 8.8 $ 139,752 $ (14,577 ) $ 125,175 8.9
Schedule of intangible assets	The following table presents details of our intangible assets (in thousands): June 30, 2020 December 31, 2019 Cost Accumulated Net Weighted-Average Cost Accumulated Net Weighted-Average Customer relationships $ 23,763 $ (6,541 ) $ 17,222 10.0 $ 23,763 $ (5,141 ) $ 18,622 10.0 Developed technology 161,110 (16,188 ) 144,922 8.6 84,396 (8,476 ) 75,920 8.6 Non-compete agreement 286 (200 ) 86 5.0 286 (172 ) 114 5.0 Trade name 576 (559 ) 17 2.7 576 (480 ) 96 2.7 Patent licensing agreement 496 (87 ) 409 15.0 496 (70 ) 426 15.0 Favorable leases 247 (247 ) — 2.2 247 (238 ) 9 2.2 In-process research and development 29,988 — 29,988 n/a 29,988 — 29,988 n/a $ 216,466 $ (23,822 ) $ 192,644 8.8 $ 139,752 $ (14,577 ) $ 125,175 8.9
Summary of estimated future amortization expense of intangible assets with finite lives	The following table summarizes our estimated future amortization expense of intangible assets with finite lives as of June 30, 2020 (in thousands): 2020 (remainder of year) $ 11,207 2021 22,793 2022 21,087 2023 20,074 2024 19,796 Thereafter 67,699 Total estimated future amortization expense $ 162,656

Balance sheet components (Table

Balance sheet components (Tables)	6 Months Ended
	Jun. 30, 2020
Balance Sheet Related Disclosures [Abstract]
Schedule of property and equipment	Property and equipment consisted of the following (in thousands): June 30, 2020 December 31, 2019 Leasehold improvements $ 23,251 $ 18,352 Laboratory equipment 30,668 24,873 Computer equipment 6,760 5,995 Software 2,611 2,611 Furniture and fixtures 1,277 1,198 Automobiles 58 58 Construction-in-progress 9,070 10,795 Total property and equipment, gross 73,695 63,882 Accumulated depreciation and amortization (30,314 ) (26,135 ) Total property and equipment, net $ 43,381 $ 37,747
Schedule of accrued liabilities	Accrued liabilities consisted of the following (in thousands): June 30, 2020 December 31, 2019 Accrued compensation and related expenses $ 20,144 $ 16,440 Compensation and other liabilities associated with business combinations 64,976 30,560 Deferred revenue 1,726 1,429 Other 12,644 16,385 Total accrued liabilities $ 99,490 $ 64,814

Fair value measurements (Tables

Fair value measurements (Tables)	6 Months Ended
	Jun. 30, 2020
Fair Value Disclosures [Abstract]
Financial instruments at fair value on a recurring basis	The following tables set forth the fair value of our consolidated financial instruments that were measured at fair value on a recurring basis (in thousands): June 30, 2020 Amortized Cost Unrealized Estimated Fair Value Gains Losses Level 1 Level 2 Level 3 Financial assets: Money market funds $ 132,990 $ — $ — $ 132,990 $ 132,990 $ — $ — Certificates of deposit 300 — — 300 — 300 — U.S. treasury notes 197,721 570 — 198,291 198,291 — — U.S. government agency securities 55,340 2 — 55,342 — 55,342 — Total financial assets $ 386,351 $ 572 $ — $ 386,923 $ 331,281 $ 55,642 $ — Financial liabilities: Stock payable liability $ 43,625 $ — $ — $ 43,625 Contingent consideration 18,018 — — 18,018 Total financial liabilities $ 61,643 $ — $ — $ 61,643 June 30, 2020 Reported as: Cash equivalents $ 126,647 Restricted cash 6,343 Marketable securities 253,933 Total cash equivalents, restricted cash, and marketable securities $ 386,923 Accrued liabilities $ 15,441 Other long-term liabilities $ 46,202 December 31, 2019 Amortized Cost Unrealized Estimated Fair Value Gains Losses Level 1 Level 2 Level 3 Financial assets: Money market funds $ 39,396 $ — $ — $ 39,396 $ 39,396 $ — $ — Certificates of deposit 300 — — 300 — 300 — U.S. treasury notes 150,627 — (15 ) 150,612 150,612 — — U.S. government agency securities 193,302 6 — 193,308 — 193,308 — Total financial assets $ 383,625 $ 6 $ (15 ) $ 383,616 $ 190,008 $ 193,608 $ — Financial liabilities: Contingent consideration $ 11,300 — — $ 11,300 Total financial liabilities $ 11,300 — — $ 11,300 December 31, 2019 Reported as: Cash equivalents $ 136,997 Restricted cash 6,183 Marketable securities 240,436 Total cash equivalents, restricted cash, and marketable securities $ 383,616 Accrued liabilities $ 3,300 Other long-term liabilities $ 8,000

Commitments and contingencies (

Commitments and contingencies (Tables)	6 Months Ended
	Jun. 30, 2020
Commitments and Contingencies Disclosure [Abstract]
Components of lease cost	The components of lease costs, which were included in cost of revenue, research and development, selling and marketing and general and administrative expenses on our consolidated statements of operations were as follows (in thousands): Three Months Ended June 30, Six Months Ended June 30, 2020 2019 2020 2019 Operating lease costs $ 2,653 $ 2,564 $ 5,268 $ 5,081 Sublease income — (43 ) — (86 ) Total operating lease costs 2,653 2,521 5,268 4,995 Finance lease costs 475 391 959 811 Total lease costs $ 3,128 $ 2,912 $ 6,227 $ 5,806
Schedule of future minimum payments under operating leases	Future minimum payments under non-cancelable operating leases as of June 30, 2020 are as follows (in thousands): 2020 (remainder of year) $ 5,749 2021 11,693 2022 10,922 2023 10,424 2024 10,560 Thereafter 18,459 Future non-cancelable minimum operating lease payments 67,807 Less: imputed interest (19,334 ) Total operating lease liabilities 48,473 Less: current portion (6,339 ) Operating lease obligations, net of current portion $ 42,134
Schedule of future minimum lease payments under finance leases	Future payments under finance leases at June 30, 2020 are as follows (in thousands): 2020 (remainder of year) $ 741 2021 611 2022 612 Total finance lease obligations 1,964 Less: interest (108 ) Present value of net minimum finance lease payments 1,856 Less: current portion (977 ) Finance lease obligations, net of current portion $ 879
Components of debt	The Convertible Senior Notes as of June 30, 2020 consisted of the following (in thousands): Outstanding principal $ 350,000 Unamortized debt discount and issuance costs (73,908 ) Net carrying amount, liability component $ 276,092

Stockholders' equity (Tables)

Stockholders' equity (Tables)	6 Months Ended
	Jun. 30, 2020
Equity [Abstract]
Schedule of convertible preferred and common stock	Shares of convertible preferred and common stock were as follows (in thousands): Three Months Ended June 30, Six Months Ended June 30, 2020 2019 2020 2019 Convertible preferred stock: Shares outstanding, beginning of period 125 125 125 3,459 Conversion into common stock — — — (3,334 ) Shares outstanding, end of period 125 125 125 125 Common stock: Shares outstanding, beginning of period 101,920 89,601 98,796 75,481 Common stock issued in connection with public offering 23,058 — 23,058 10,350 Common stock issued on exercise of stock options, net 130 80 308 340 Common stock issued pursuant to vesting of RSUs 3,055 1,124 3,481 1,245 Common stock issued pursuant to exercises of warrants 6 4 148 19 Common stock issued pursuant to employee stock purchase plan 342 235 342 235 Common stock issued pursuant to business combinations 2,778 2,719 5,156 2,759 Common stock issued upon conversion of preferred stock — — — 3,334 Shares outstanding, end of period 131,289 93,763 131,289 93,763

Stock incentive plans (Tables)

Stock incentive plans (Tables)	6 Months Ended
	Jun. 30, 2020
Share-based Payment Arrangement [Abstract]
Schedule of activity under the plans	Activity under the 2010 Plan and the 2015 Plan is set forth below (in thousands, except per share amounts and years): Shares Available For Grant Stock Options Outstanding Weighted-Average Exercise Price Per Share Weighted-Average Remaining Contractual Life (Years) Aggregate Intrinsic Value Balances at December 31, 2019 5,444 3,542 $ 9.49 6.1 $ 24,966 Additional shares reserved 5,027 — Options granted (282 ) 282 16.28 Options exercised — (308 ) 7.04 RSUs and PRSUs granted (1) (3,150 ) — RSUs and PRSUs cancelled 337 — Balances at June 30, 2020 7,376 3,516 $ 10.26 6.1 $ 70,414 Options exercisable at June 30, 2020 2,940 $ 9.30 5.5 $ 61,695 Options vested and expected to vest at June 30, 2020 3,414 $ 10.08 6.0 $ 68,992 (1) Includes the changes in the Time-based RSUs and PRSUs granted as a part of the Singular Bio acquisition in June 2019 which are based on a fixed dollar value. The number of shares issued will be variable until the awards vest. See further details in Note 4, "Business combinations."
Summary of RSU activity	The following table summarizes RSU activity, which includes the changes in Time-based RSUs and PRSUs granted in connection with our acquisition of Singular Bio (in thousands, except per share data): Number of Shares Weighted- Average Grant Date Fair Value Per Share Balance at December 31, 2019 8,885 $ 15.17 RSUs granted 3,739 $ 15.35 Time-based RSUs and PRSUs granted - Singular Bio (1) (863 ) $ 23.58 PRSUs granted 274 $ 16.17 RSUs vested (3,481 ) $ 15.32 RSUs cancelled (337 ) $ 18.83 Balance at June 30, 2020 8,217 $ 14.19 (1) Includes the changes in the Time-based RSUs and PRSUs granted as a part of the Singular Bio acquisition in June 2019 which are based on a fixed dollar value. The number of shares issued will be variable until the awards vest which are adjusted above. The weighted-average grant date fair value per share reflects the fair value pricing of the full award. See further details in Note 4, "Business combinations."
Summary of stock based compensation expense	The following table summarizes stock-based compensation expense included in the consolidated statements of operations (in thousands): Three Months Ended June 30, Six Months Ended June 30, 2020 2019 2020 2019 Cost of revenue $ 2,356 $ 2,205 $ 3,217 $ 2,856 Research and development 41,565 6,767 63,769 8,572 Selling and marketing 3,298 2,914 5,120 4,157 General and administrative 4,627 2,431 9,018 3,955 Total stock-based compensation expense $ 51,846 $ 14,317 $ 81,124 $ 19,540

Net loss per share (Tables)

Net loss per share (Tables)	6 Months Ended
	Jun. 30, 2020
Earnings Per Share [Abstract]
Schedule of earnings per share, basic and diluted	The following table presents the calculation of basic and diluted net loss per share (in thousands, except per share amounts): Three Months Ended June 30, Six Months Ended June 30, 2020 2019 2020 2019 Net loss $ (166,403 ) $ (48,676 ) $ (264,930 ) $ (86,353 ) Shares used in computing net loss per share, basic and diluted 129,023 90,863 112,765 85,148 Net loss per share, basic and diluted $ (1.29 ) $ (0.54 ) $ (2.35 ) $ (1.01 )
Schedule of antidilutive securities excluded from computation of earnings per share	The following common stock equivalents have been excluded from diluted net loss per share because their inclusion would be anti-dilutive (in thousands): Three Months Ended June 30, Six Months Ended June 30, 2020 2019 2020 2019 Shares of common stock subject to outstanding options 3,416 3,669 3,447 3,714 Shares of common stock subject to outstanding warrants 369 593 429 601 Shares of common stock subject to outstanding RSUs 6,403 4,569 5,716 4,350 Shares of common stock subject to outstanding PRSUs 2,379 — 2,586 — Shares of common stock pursuant to ESPP 313 46 318 55 Shares of common stock underlying Series A convertible preferred stock 125 125 125 1,288 Shares of common stock subject to convertible senior notes exercise 11,555 — 11,555 — Total shares of common stock equivalents 24,560 9,002 24,176 10,008

Geographic information (Tables)

Geographic information (Tables)	6 Months Ended
	Jun. 30, 2020
Segments, Geographical Areas [Abstract]
Schedule of revenue by country	The following presents revenue by country (in thousands): Three Months Ended June 30, Six Months Ended June 30, 2020 2019 2020 2019 United States $ 43,334 $ 50,368 $ 103,140 $ 88,013 Canada 797 882 2,016 1,847 Rest of world 2,060 2,225 5,283 4,168 Total revenue $ 46,191 $ 53,475 $ 110,439 $ 94,028

Organization and description _2

Organization and description of business - Additional Information (Details) gene in Thousands	6 Months Ended	12 Months Ended
	Jun. 30, 2020Segmentgene	Dec. 31, 2019business
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Number of genes | gene	20
Number of businesses acquired | business		4
Number of operating segments | Segment	1

Summary of significant accoun_4

Summary of significant accounting policies - Summary of significant customers as percentage of total revenue and total accounts receivable (Details) - Customer Concentration Risk - Revenue	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Medicare
Summary Of Significant Accounting Policies [Line Items]
Concentration risk	20.00%	23.00%	21.00%	22.00%
United Healthcare
Summary Of Significant Accounting Policies [Line Items]
Concentration risk		10.00%		10.00%

Summary of significant accoun_5

Summary of significant accounting policies - Reconciliation of cash, cash equivalents and restricted cash (Details) - USD ($) $ in Thousands	Jun. 30, 2020	Dec. 31, 2019	Jun. 30, 2019	Dec. 31, 2018
Accounting Policies [Abstract]
Cash and cash equivalents	$ 168,203	$ 151,389
Restricted cash	6,343	6,183
Total cash, cash equivalents and restricted cash	$ 174,546	$ 157,572	$ 253,243	$ 118,164

Summary of significant accoun_6

Summary of significant accounting policies - Additional information (Details) - USD ($) $ in Thousands	3 Months Ended			6 Months Ended
	Jun. 30, 2020	Mar. 31, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019	Dec. 31, 2019	Mar. 31, 2019	Dec. 31, 2018
Business Acquisition [Line Items]
Inventory	$ 11,100			$ 11,100		$ 6,600
Decrease to stockholders' equity	(464,195)		$ (341,503)	(464,195)	$ (341,503)	(379,640)
Other income (expense), net	(21,436)		1,381	(16,728)	2,019
Immaterial error related to classification of Indemnification from acquisition | Restatement adjustment
Business Acquisition [Line Items]
Long-term liabilities		$ 10,100
Other income (expense), net		300
Additional paid-in capital:
Business Acquisition [Line Items]
Decrease to stockholders' equity	$ (1,487,217)	(1,182,033)	$ (944,559)	$ (1,487,217)	$ (944,559)	(1,138,316)	$ (870,784)	$ (678,548)
Additional paid-in capital: | Immaterial error related to classification of Indemnification from acquisition | Restatement adjustment
Business Acquisition [Line Items]
Decrease to stockholders' equity		$ 10,400				$ 10,387

Revenue, accounts receivable _3

Revenue, accounts receivable and deferred revenue - Schedule of disaggregated revenue by payer category (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Disaggregation of Revenue [Line Items]
Total revenue	$ 46,191	$ 53,475	$ 110,439	$ 94,028
Test revenue
Disaggregation of Revenue [Line Items]
Total revenue	45,099	52,302	108,177	91,921
Test revenue | Institutions
Disaggregation of Revenue [Line Items]
Total revenue	9,531	9,814	23,028	17,968
Test revenue | Patient - direct
Disaggregation of Revenue [Line Items]
Total revenue	4,298	4,056	10,089	7,797
Test revenue | Patient - insurance
Disaggregation of Revenue [Line Items]
Total revenue	31,270	38,432	75,060	66,156
Other revenue
Disaggregation of Revenue [Line Items]
Total revenue	$ 1,092	$ 1,173	$ 2,262	$ 2,107

Revenue, accounts receivable _4

Revenue, accounts receivable and deferred revenue - Schedule of change in estimate (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Total revenue	$ 46,191	$ 53,475	$ 110,439	$ 94,028
Loss from operations	$ 142,082	$ 51,886	$ 239,866	$ 88,093
Net loss per share, basic and diluted	$ 1.29	$ 0.54	$ 2.35	$ 1.01
Change in estimate of revenue recognition
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Total revenue	$ 900	$ 2,400	$ 2,300	$ 2,800
Loss from operations	$ (900)	$ (2,400)	$ (2,300)	$ (2,800)
Net loss per share, basic and diluted	$ (0.01)	$ (0.03)	$ (0.02)	$ (0.03)

Revenue, accounts receivable _5

Revenue, accounts receivable and deferred revenue - Additional information (Details) - USD ($) $ in Millions	1 Months Ended		3 Months Ended	6 Months Ended
	May 31, 2020	Apr. 30, 2020	Jun. 30, 2020	Jun. 30, 2020
Restructuring Cost and Reserve [Line Items]
Revenue re-requisition rights period				90 days
One-time termination costs
Restructuring Cost and Reserve [Line Items]
Positions eliminated, percent of total workforce		8.00%
Restructuring charges			$ 3.8
Reduction in officer salary	20.00%
CARES Act
Restructuring Cost and Reserve [Line Items]
Income received under the CARES Act		$ 3.8

Business combinations - Singula

Business combinations - Singular Bio (Details) - USD ($) shares in Thousands, $ in Thousands	1 Months Ended		3 Months Ended		6 Months Ended
	Apr. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Business Acquisition [Line Items]
Business combination, total purchase consideration	$ 65,913
Total stock-based compensation expense			$ 51,846	$ 14,317	$ 81,124	$ 19,540
Singular Bio
Business Acquisition [Line Items]
Percentage of diluted interest acquired		100.00%		100.00%		100.00%
Business combination, total purchase consideration		$ 57,300
Common stock transferred		$ 53,900		$ 53,900		$ 53,900
Business acquisition common stock issued (in shares)		2,500
Stock incentive plans
Business Acquisition [Line Items]
Vesting period					4 years
Stock incentive plans | Singular Bio
Business Acquisition [Line Items]
RSUs granted (in shares)					4,400
Fair value of units vested			26,800		$ 26,800
RSU
Business Acquisition [Line Items]
RSUs granted (in shares)					3,739
Vested stock units awarded (in shares)					3,481
RSU | Stock incentive plans
Business Acquisition [Line Items]
Vesting period					3 years
RSU | Stock incentive plans | Singular Bio
Business Acquisition [Line Items]
Business acquisition, value of units granted		$ 90,000		90,000		90,000
RSU - Time based | Stock incentive plans | Singular Bio
Business Acquisition [Line Items]
Business acquisition, value of units granted		45,000	48,600	45,000	$ 48,600	45,000
Total stock-based compensation expense			$ 10,900		$ 18,500
Vested stock units awarded (in shares)			900		900
PRSU
Business Acquisition [Line Items]
RSUs granted (in shares)					274
PRSU | Stock incentive plans | Singular Bio
Business Acquisition [Line Items]
Business acquisition, value of units granted		$ 45,000	$ 54,400	$ 45,000	$ 54,400	$ 45,000
Vesting period		12 months			18 months
Total stock-based compensation expense			$ 18,900		$ 30,100
Vested stock units awarded (in shares)			600		600
First anniversary | RSU | Stock incentive plans
Business Acquisition [Line Items]
Vesting rate upon anniversaries					33.33%
First anniversary | RSU | Stock incentive plans | Singular Bio
Business Acquisition [Line Items]
Vesting rate upon anniversaries		33.33%			33.33%
Second anniversary | RSU | Stock incentive plans
Business Acquisition [Line Items]
Vesting rate upon anniversaries					33.33%
Second anniversary | RSU | Stock incentive plans | Singular Bio
Business Acquisition [Line Items]
Vesting rate upon anniversaries		33.33%			33.33%
Third anniversary | RSU | Stock incentive plans
Business Acquisition [Line Items]
Vesting rate upon anniversaries					33.33%
Third anniversary | RSU | Stock incentive plans | Singular Bio
Business Acquisition [Line Items]
Vesting rate upon anniversaries		33.33%			33.33%

Business combinations - Jungla

Business combinations - Jungla (Details) - USD ($) $ in Thousands, shares in Millions	1 Months Ended		3 Months Ended	6 Months Ended
	Apr. 30, 2020	Jul. 31, 2019	Jun. 30, 2020	Jun. 30, 2020
Business Acquisition [Line Items]
Business combination, total purchase consideration	$ 65,913
Hold-back consideration - common stock	$ 6,173
Jungla
Business Acquisition [Line Items]
Percentage of diluted interest acquired		100.00%
Business combination, total purchase consideration		$ 59,000
Common stock transferred		$ 44,900
Hold-back consideration - common stock			$ 6,000
Indemnification obligations | Jungla
Business Acquisition [Line Items]
Business acquisition common stock issued (in shares)		0.2		0.2
Ongoing development post-close milestones | Jungla
Business Acquisition [Line Items]
Contingent consideration		$ 10,700
Business acquisition, expected milestone duration		2 years

Business combinations - Clear G

Business combinations - Clear Genetics (Details) - USD ($) $ in Thousands, shares in Millions	1 Months Ended		3 Months Ended	6 Months Ended
	Apr. 30, 2020	Nov. 30, 2019	Jun. 30, 2020	Jun. 30, 2020
Business Acquisition [Line Items]
Business combination, total purchase consideration	$ 65,913
Hold-back consideration - cash	1,385
Hold-back consideration - common stock	$ 6,173
Clear Genetics
Business Acquisition [Line Items]
Percentage of diluted interest acquired		100.00%
Business combination, total purchase consideration		$ 50,100
Common stock issued pursuant to business combinations (in shares)			0.1
Hold-back consideration - common stock			$ 8,500
Indemnification obligations | Clear Genetics
Business Acquisition [Line Items]
Hold-back consideration - cash		$ 200
Business acquisition common stock issued (in shares)		0.4		0.3

Business combinations - Diploid

Business combinations - Diploid (Details) - USD ($) shares in Thousands, $ in Thousands	1 Months Ended			6 Months Ended	12 Months Ended
	Jun. 30, 2020	Apr. 30, 2020	Mar. 31, 2020	Jun. 30, 2020	Dec. 31, 2019
Business Acquisition [Line Items]
Business combination, total purchase consideration		$ 65,913
Useful life				8 years 9 months 18 days	8 years 10 months 24 days
Hold-back consideration - common stock		$ 6,173
Goodwill	$ 211,225			$ 211,225	$ 126,777
Diploid
Business Acquisition [Line Items]
Percentage of diluted interest acquired	100.00%			100.00%
Business combination, total purchase consideration			$ 82,314
Useful life			9 years
Hold-back consideration - common stock			$ 7,538
Contingent consideration	$ 12,800			$ 12,800
Goodwill	$ 50,655			$ 50,655
Indemnification obligations | Diploid
Business Acquisition [Line Items]
Business acquisition common stock issued (in shares)			400
First anniversary | Stock incentive plans | Diploid
Business Acquisition [Line Items]
Vesting rate upon anniversaries	50.00%
Second anniversary | Stock incentive plans | Diploid
Business Acquisition [Line Items]
Vesting rate upon anniversaries	50.00%
RSU
Business Acquisition [Line Items]
RSUs granted (in shares)				3,739
RSU | Stock incentive plans | Diploid
Business Acquisition [Line Items]
RSUs granted (in shares)	200
Business acquisition, value of units granted	$ 3,600			$ 3,600
RSU | First anniversary | Stock incentive plans
Business Acquisition [Line Items]
Vesting rate upon anniversaries				33.33%
RSU | Second anniversary | Stock incentive plans
Business Acquisition [Line Items]
Vesting rate upon anniversaries				33.33%

Business combinations - Summary

Business combinations - Summary of the purchase price and post-combination expense (Details) - USD ($) $ in Thousands	1 Months Ended
	Apr. 30, 2020	Mar. 31, 2020
Purchase Price
Cash transferred	$ 25,434
Hold-back consideration - cash	1,385
Hold-back consideration - common stock	6,173
Contingent consideration	1,994
Common stock transferred	30,927
Total	65,913
Diploid
Purchase Price
Cash transferred		$ 32,323
Hold-back consideration - common stock		7,538
Common stock transferred		42,453
Total		$ 82,314
Genelex
Purchase Price
Cash transferred	972
Hold-back consideration - cash	0
Hold-back consideration - common stock	781
Contingent consideration	1,994
Common stock transferred	9,463
Total	13,210
YouScript
Purchase Price
Cash transferred	24,462
Hold-back consideration - cash	1,385
Hold-back consideration - common stock	5,392
Contingent consideration	0
Common stock transferred	21,464
Total	$ 52,703

Business combinations - Summa_2

Business combinations - Summary of fair values of assets acquired and liabilities assumed (Details) - USD ($) $ in Thousands	Jun. 30, 2020	Apr. 30, 2020	Dec. 31, 2019
Business Acquisition [Line Items]
Goodwill	$ 211,225		$ 126,777
Diploid
Business Acquisition [Line Items]
Cash	124
Accounts receivable	26
Intangible assets	41,789
Total identifiable assets acquired	41,939
Accounts payable	(30)
Deferred tax liability	(10,250)
Net identifiable assets acquired	31,659
Goodwill	50,655
Total purchase price	$ 82,314
Genelex
Business Acquisition [Line Items]
Cash		$ 33
Accounts receivable		221
Prepaid expenses and other current assets		0
Operating lease assets		0
Intangible assets		9,209
Total identifiable assets acquired		9,463
Current liabilities		(320)
Deferred tax liability		0
Other long-term liabilities		0
Net identifiable assets acquired		9,143
Goodwill		4,067
Total purchase price		13,210
YouScript
Business Acquisition [Line Items]
Cash		24
Accounts receivable		56
Prepaid expenses and other current assets		70
Operating lease assets		355
Intangible assets		25,716
Total identifiable assets acquired		26,221
Current liabilities		(481)
Deferred tax liability		(2,600)
Other long-term liabilities		(163)
Net identifiable assets acquired		22,977
Goodwill		29,726
Total purchase price		52,703
Genelex and YouScript
Business Acquisition [Line Items]
Cash		57
Accounts receivable		277
Prepaid expenses and other current assets		70
Operating lease assets		355
Intangible assets		34,925
Total identifiable assets acquired		35,684
Current liabilities		(801)
Deferred tax liability		(2,600)
Other long-term liabilities		(163)
Net identifiable assets acquired		32,120
Goodwill		33,793
Total purchase price		$ 65,913

Business combinations - Genelex

Business combinations - Genelex and YouScript (Details) - USD ($) $ in Thousands, shares in Millions	1 Months Ended	6 Months Ended	12 Months Ended
	Apr. 30, 2020	Jun. 30, 2020	Dec. 31, 2019
Business Acquisition [Line Items]
Business combination, total purchase consideration	$ 65,913
Cash transferred	25,434
Hold-back consideration - common stock	$ 6,173
Weighted-Average Useful Life (in Years)		8 years 9 months 18 days	8 years 10 months 24 days
Goodwill		$ 211,225	$ 126,777
Genelex
Business Acquisition [Line Items]
Percentage of diluted interest acquired	100.00%
Business combination, total purchase consideration	$ 13,210
Cash transferred	972
Hold-back consideration - common stock	$ 781
Business acquisition, expected milestone duration	4 years
Contingent consideration	$ 2,000	2,600
Weighted-Average Useful Life (in Years)	8 years
Goodwill	$ 4,067
YouScript
Business Acquisition [Line Items]
Percentage of diluted interest acquired	100.00%
Business combination, total purchase consideration	$ 52,703
Cash transferred	24,462
Hold-back consideration - common stock	$ 5,392
Weighted-Average Useful Life (in Years)	8 years
Goodwill	$ 29,726
Genelex and YouScript
Business Acquisition [Line Items]
Hold-back consideration - common stock	6,200	16,000
Transaction costs		$ 900
Goodwill	$ 33,793
Indemnification obligations | Genelex
Business Acquisition [Line Items]
Business acquisition common stock issued (in shares)	0.1
Indemnification obligations | YouScript
Business Acquisition [Line Items]
Business acquisition common stock issued (in shares)	0.5
Hold-back consideration - common stock	$ 1,400

Business combinations - ArcherD

Business combinations - ArcherDX (Details) - USD ($)	1 Months Ended		3 Months Ended	6 Months Ended
	Jun. 30, 2020	Apr. 30, 2020	Sep. 30, 2020	Jun. 30, 2020	Jun. 30, 2019
Business Acquisition [Line Items]
Cash transferred		$ 25,434,000
Proceeds from issuance of common stock				$ 6,760,000	$ 5,123,000
Forecast | ArcherDX
Business Acquisition [Line Items]
Business acquisition common stock issued (in shares)			30,000,000
Cash transferred			$ 325,000,000
Milestone achievement agreement | Forecast | ArcherDX
Business Acquisition [Line Items]
Business acquisition common stock issued (in shares)			27,000,000
Debt financing contingency | ArcherDX
Business Acquisition [Line Items]
Warrants issued (in shares)	1,000,000			1,000,000
Exercise price (in dollars per share)	$ 16.85			$ 16.85
Private placement | Common stock: | ArcherDX
Business Acquisition [Line Items]
Proceeds from issuance of common stock	$ 275,000,000
Shares issued price per share (in dollars per share)	$ 16.85			$ 16.85
Acquisition financing commitment | ArcherDX
Business Acquisition [Line Items]
Maximum borrowing capacity	$ 200,000,000			$ 200,000,000

Goodwill and intangible asset_2

Goodwill and intangible assets - Summary of goodwill (Details) $ in Thousands	6 Months Ended
	Jun. 30, 2020USD ($)
Goodwill [Line Items]
Beginning Balance	$ 126,777
Ending Balance	211,225
Diploid
Goodwill [Line Items]
Goodwill acquired	50,655
Ending Balance	50,655
Genelex
Goodwill [Line Items]
Goodwill acquired	4,067
YouScript
Goodwill [Line Items]
Goodwill acquired	$ 29,726

Goodwill and intangible asset_3

Goodwill and intangible assets - Schedule of intangible assets (Details) - USD ($) $ in Thousands	6 Months Ended	12 Months Ended
	Jun. 30, 2020	Dec. 31, 2019
Finite-Lived Intangible Assets [Line Items]
Accumulated Amortization	$ (23,822)	$ (14,577)
Total estimated future amortization expense	$ 162,656
Weighted-Average Useful Life (in Years)	8 years 9 months 18 days	8 years 10 months 24 days
Cost	$ 216,466	$ 139,752
Net	192,644	125,175
Customer relationships
Finite-Lived Intangible Assets [Line Items]
Cost, finite intangible	23,763	23,763
Accumulated Amortization	(6,541)	(5,141)
Total estimated future amortization expense	$ 17,222	$ 18,622
Weighted-Average Useful Life (in Years)	10 years	10 years
Developed technology
Finite-Lived Intangible Assets [Line Items]
Cost, finite intangible	$ 161,110	$ 84,396
Accumulated Amortization	(16,188)	(8,476)
Total estimated future amortization expense	$ 144,922	$ 75,920
Weighted-Average Useful Life (in Years)	8 years 7 months 6 days	8 years 7 months 6 days
Non-compete agreement
Finite-Lived Intangible Assets [Line Items]
Cost, finite intangible	$ 286	$ 286
Accumulated Amortization	(200)	(172)
Total estimated future amortization expense	$ 86	$ 114
Weighted-Average Useful Life (in Years)	5 years	5 years
Trade name
Finite-Lived Intangible Assets [Line Items]
Cost, finite intangible	$ 576	$ 576
Accumulated Amortization	(559)	(480)
Total estimated future amortization expense	$ 17	$ 96
Weighted-Average Useful Life (in Years)	2 years 8 months 12 days	2 years 8 months 12 days
Patent licensing agreement
Finite-Lived Intangible Assets [Line Items]
Cost, finite intangible	$ 496	$ 496
Accumulated Amortization	(87)	(70)
Total estimated future amortization expense	$ 409	$ 426
Weighted-Average Useful Life (in Years)	15 years	15 years
Favorable leases
Finite-Lived Intangible Assets [Line Items]
Cost, finite intangible	$ 247	$ 247
Accumulated Amortization	(247)	(238)
Total estimated future amortization expense	$ 0	$ 9
Weighted-Average Useful Life (in Years)	2 years 2 months 12 days	2 years 2 months 12 days
In-process research and development
Finite-Lived Intangible Assets [Line Items]
In-process research and development	$ 29,988	$ 29,988

Goodwill and intangible asset_4

Goodwill and intangible assets - Additional information (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Goodwill and Intangible Assets Disclosure [Abstract]
Amortization expense	$ 5.7	$ 1.3	$ 9.2	$ 2.6

Goodwill and intangible asset_5

Goodwill and intangible assets - Summary of estimated future amortization expense of intangible assets with finite lives (Details) $ in Thousands	Jun. 30, 2020USD ($)
Goodwill and Intangible Assets Disclosure [Abstract]
2020 (remainder of year)	$ 11,207
2021	22,793
2022	21,087
2023	20,074
2024	19,796
Thereafter	67,699
Total estimated future amortization expense	$ 162,656

Balance sheet components - Sche

Balance sheet components - Schedule of property and equipment (Details) - USD ($) $ in Thousands	Jun. 30, 2020	Dec. 31, 2019
Property and equipment
Total property and equipment, gross	$ 73,695	$ 63,882
Accumulated depreciation and amortization	(30,314)	(26,135)
Total property and equipment, net	43,381	37,747
Leasehold improvements
Property and equipment
Total property and equipment, gross	23,251	18,352
Laboratory equipment
Property and equipment
Total property and equipment, gross	30,668	24,873
Computer equipment
Property and equipment
Total property and equipment, gross	6,760	5,995
Software
Property and equipment
Total property and equipment, gross	2,611	2,611
Furniture and fixtures
Property and equipment
Total property and equipment, gross	1,277	1,198
Automobiles
Property and equipment
Total property and equipment, gross	58	58
Construction-in-progress
Property and equipment
Total property and equipment, gross	$ 9,070	$ 10,795

Balance sheet components - Addi

Balance sheet components - Additional information (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Balance Sheet Related Disclosures [Abstract]
Depreciation	$ 2.3	$ 1.8	$ 4.4	$ 3.4

Balance sheet components - Sc_2

Balance sheet components - Schedule of accrued liabilities (Details) - USD ($) $ in Thousands	Jun. 30, 2020	Dec. 31, 2019
Balance Sheet Related Disclosures [Abstract]
Accrued compensation and related expenses	$ 20,144	$ 16,440
Compensation and other liabilities associated with business combinations	64,976	30,560
Deferred revenue	1,726	1,429
Other	12,644	16,385
Total accrued liabilities	$ 99,490	$ 64,814

Fair value measurements - Finan

Fair value measurements - Financial instruments at fair value on a recurring basis (Details) - USD ($) $ in Thousands	Jun. 30, 2020	Dec. 31, 2019
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Amortized Cost	$ 386,351	$ 383,625
Unrealized Gains	572	6
Unrealized Losses		(15)
Financial assets:	386,923	383,616
Cash equivalents	126,647	136,997
Restricted cash	6,343	6,183
Marketable securities	253,933	240,436
Accrued liabilities	99,490	64,814
Other long-term liabilities	49,428	8,000
Recurring basis
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total financial assets	386,923	383,616
Total financial liabilities	61,643	11,300
Recurring basis | Level 1
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total financial assets	331,281	190,008
Recurring basis | Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total financial assets	55,642	193,608
Recurring basis | Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total financial liabilities	61,643	11,300
Money market funds
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Amortized Cost	132,990	39,396
Money market funds | Recurring basis
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Financial assets:	132,990	39,396
Money market funds | Recurring basis | Level 1
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Financial assets:	132,990	39,396
Certificates of deposit
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Amortized Cost	300	300
Certificates of deposit | Recurring basis
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Financial assets:	300	300
Certificates of deposit | Recurring basis | Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Financial assets:	300	300
U.S. treasury notes
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Amortized Cost	197,721	150,627
Unrealized Gains	570
Unrealized Losses		(15)
U.S. treasury notes | Recurring basis
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Financial assets:	198,291	150,612
U.S. treasury notes | Recurring basis | Level 1
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Financial assets:	198,291	150,612
U.S. government agency securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Amortized Cost	55,340	193,302
Unrealized Gains	2	6
U.S. government agency securities | Recurring basis
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Financial assets:	55,342	193,308
U.S. government agency securities | Recurring basis | Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Financial assets:	55,342	193,308
Stock payable liability | Recurring basis
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total financial liabilities	43,625
Stock payable liability | Recurring basis | Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total financial liabilities	43,625
Contingent consideration
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Accrued liabilities	15,441	3,300
Other long-term liabilities	46,202	8,000
Contingent consideration | Recurring basis
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total financial liabilities	18,018	11,300
Contingent consideration | Recurring basis | Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total financial liabilities	$ 18,018	$ 11,300

Fair value measurements - Addit

Fair value measurements - Additional information (Details)	3 Months Ended	6 Months Ended
	Jun. 30, 2020USD ($)security	Jun. 30, 2020USD ($)security	Apr. 30, 2020USD ($)	Dec. 31, 2019USD ($)	Jul. 31, 2019USD ($)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Transfers of assets and liabilities between Level 1, Level 2 and Level 3	$ 0	$ 0		$ 0
Fair value of investments with unrealized losses		$ 80,200,000
Number of securities that are in continuous unrealized loss position for more than one year | security	0	0
Change in fair value, expense	$ 25,400,000	$ 21,700,000
Change in fair value, statement of operations location	us-gaap:OtherNonrecurringIncomeExpense	us-gaap:OtherNonrecurringIncomeExpense
Level 3 | Contingent consideration | Ongoing development post-close milestones | Jungla
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Contingent obligation, fair value	$ 15,400,000	$ 15,400,000			$ 10,700,000
Level 3 | Contingent consideration | Ongoing development post-close milestones | Genelex
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Contingent obligation, fair value	$ 2,600,000	$ 2,600,000	$ 2,000,000

Commitments and contingencies -

Commitments and contingencies - Operating lease - Additional information (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019	Dec. 31, 2015
Lessor, Lease, Description [Line Items]
Weighted-average remaining lease term	5 years 10 months 24 days		5 years 10 months 24 days
Weighted-average discount rate	11.50%		11.50%
Operating lease, cash payments	$ 2.7	$ 2.5	$ 5.4	$ 4.9
New Leases | Office Facility In San Francisco
Lessor, Lease, Description [Line Items]
Additional term of lease					10 years
Lease term					10 years
Security Deposit					$ 4.6

Commitments and contingencies_2

Commitments and contingencies - Components of lease cost (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Commitments and Contingencies Disclosure [Abstract]
Operating lease costs	$ 2,653	$ 2,564	$ 5,268	$ 5,081
Sublease income	0	(43)	0	(86)
Total operating lease costs	2,653	2,521	5,268	4,995
Finance lease costs	475	391	959	811
Total lease costs	$ 3,128	$ 2,912	$ 6,227	$ 5,806

Commitments and contingencies_3

Commitments and contingencies - Schedule of future minimum payments under operating leases (Details) - USD ($) $ in Thousands	Jun. 30, 2020	Dec. 31, 2019
Future minimum lease payments under operating leases
2020 (remainder of year)	$ 5,749
2021	11,693
2022	10,922
2023	10,424
2024	10,560
Thereafter	18,459
Future non-cancelable minimum operating lease payments	67,807
Less: imputed interest	(19,334)
Total operating lease liabilities	48,473
Less: current portion	(6,339)	$ (4,870)
Operating lease obligations, net of current portion	$ 42,134	$ 42,191

Commitments and contingencies_4

Commitments and contingencies - Finance lease - Additional information (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019	Dec. 31, 2019
Commitments and Contingencies Disclosure [Abstract]
Lease term	3 years		3 years
Weighted-average remaining lease term	2 years		2 years
Weighted-average discount rate	5.60%		5.60%
Finance lease assets	$ 4.7		$ 4.7		$ 5.6
Finance lease assets, balance sheet location	us-gaap:OtherAssetsNoncurrent		us-gaap:OtherAssetsNoncurrent		us-gaap:OtherAssetsNoncurrent
Finance lease, cash payments	$ 0.6	$ 0.6	$ 1.3	$ 1.1

Commitments and contingencies_5

Commitments and contingencies - Schedule of future minimum lease payments under finance leases (Details) - USD ($) $ in Thousands	Jun. 30, 2020	Dec. 31, 2019
Future payments under the finance lease
2020 (remainder of year)	$ 741
2021	611
2022	612
Total finance lease obligations	1,964
Less: interest	(108)
Present value of net minimum finance lease payments	1,856
Less: current portion	(977)	$ (1,855)
Finance lease obligations, net of current portion	$ 879	$ 1,155

Commitments and contingencies_6

Commitments and contingencies - Debt financing - Additional information (Details) - USD ($)	1 Months Ended		3 Months Ended		6 Months Ended
	Sep. 30, 2019	Nov. 30, 2018	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Note Purchase Agreement
Long-term Purchase Commitment [Line Items]
Maximum borrowing capacity		$ 200,000,000
Maturity term		7 years
Repayment of debt	$ 85,700,000
Repayment of principal	75,000,000
Repayment of accrued interest	2,400,000
Payments of debt extinguishment costs	$ 8,900,000
Initial sale of notes | Note Purchase Agreement
Long-term Purchase Commitment [Line Items]
Maximum borrowing capacity		$ 75,000,000
Proceeds from notes sold		10,300,000
Loan and Security Agreement | Secured Debt
Long-term Purchase Commitment [Line Items]
Repayment of term loan		$ 64,700,000
Interest expense			$ 0	$ 2,000,000	$ 0	$ 3,900,000

Commitments and contingencies_7

Commitments and contingencies - Convertible Senior Notes - Additional information (Details)	1 Months Ended	3 Months Ended	6 Months Ended
	Sep. 30, 2019USD ($)Trading_dayshares	Jun. 30, 2020USD ($)$ / shares	Jun. 30, 2020USD ($)$ / shares
Convertible debt | Convertible Senior Notes
Debt Instrument [Line Items]
Aggregate principal amount | $		$ 350,000,000	$ 350,000,000
Stated interest rate		2.00%	2.00%
Conversion rate (in shares) | shares	33.6293
Conversion rate, principal | $	$ 1,000
Conversion price (in dollars per share) | $ / shares		$ 29.74	$ 29.74
Redemption price, percent of principle	100.00%
Number of trading days | Trading_day	20
Number of consecutive trading days | Trading_day	30
Threshold percentage of stock price trigger	130.00%
Number of trading days immediately after five consecutive trading days | Trading_day	5
Threshold percentage of stock price trigger, maximum	98.00%
Redemption period, number of trading days | Trading_day	30
Interest expense | $		$ 5,500,000	$ 10,900,000
Level 2
Debt Instrument [Line Items]
Convertible debt fair value | $		$ 406,900,000	$ 406,900,000

Commitments and contingencies_8

Commitments and contingencies - Components of debt (Details) - Convertible debt - Convertible Senior Notes $ in Thousands	Jun. 30, 2020USD ($)
Debt Instrument [Line Items]
Outstanding principal	$ 350,000
Unamortized debt discount and issuance costs	(73,908)
Net carrying amount, liability component	$ 276,092

Commitments and contingencies_9

Commitments and contingencies - Other commitments - Additional information (Details) $ in Millions	Jun. 30, 2020USD ($)
Service Agreements and Laboratory Supplies
Other Commitments [Line Items]
Noncancelable unconditional purchase commitments	$ 6

Stockholders' equity - Schedule

Stockholders' equity - Schedule of convertible preferred and common stock (Details) - shares shares in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Convertible preferred stock:
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Shares outstanding, beginning of period	125	125	125	3,459
Shares converted				3,334
Shares outstanding, end of period	125	125	125	125
Common stock:
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Shares outstanding, beginning of period	101,920	89,601	98,796	75,481
Shares converted				3,334
Common stock issued in connection with public offering (in shares)	23,058		23,058	10,350
Common stock issued on exercise of stock options, net (in shares)	130	80	308	340
Common stock issued pursuant to vesting of RSUs (in shares)	3,055	1,124	3,481	1,245
Common stock issued pursuant to exercises of warrants (in shares)	6	4	148	19
Common stock issued pursuant to employee stock purchase plan (in shares)	342	235	342	235
Common stock issued pursuant to business combinations (in shares)	2,778	2,719	5,156	2,759
Shares outstanding, end of period	131,289	93,763	131,289	93,763

Stockholders' equity - Addition

Stockholders' equity - Additional information (Details) - USD ($)	1 Months Ended			3 Months Ended	6 Months Ended
	Apr. 30, 2020	Mar. 31, 2019	Aug. 31, 2018	Jun. 30, 2020	Jun. 30, 2020	Jun. 30, 2019
Class of Stock [Line Items]
Proceeds from issuance of common stock, net					$ 6,760,000	$ 5,123,000
Common stock | Underwritten Public Offering
Class of Stock [Line Items]
Proceeds from issuance of common stock, net	$ 184,000,000
Number of shares sold in underwritten public offering	20,400,000
Shares issued price per share (in dollars per share)	$ 9
Net proceeds from issuance of common stock	$ 173,000,000
2018 Sales Agreement | Cowen and Company, LLC
Class of Stock [Line Items]
Proceeds from issuance of common stock, net				$ 46,000,000
Percentage of commission payable on gross proceeds			3.00%
Number of shares sold in underwritten public offering				2,600,000
Shares issued price per share (in dollars per share)				$ 17.60	$ 17.60
Net proceeds from issuance of common stock				$ 44,500,000
2018 Sales Agreement | Maximum | Cowen and Company, LLC
Class of Stock [Line Items]
Proceeds from issuance of common stock, net		$ 175,000,000	$ 75,000,000

Stock incentive plans - Additio

Stock incentive plans - Additional information (Details) - USD ($) $ / shares in Units, $ in Millions	1 Months Ended				3 Months Ended	6 Months Ended
	Jun. 30, 2020	Jul. 31, 2019	Jun. 30, 2019	Jan. 31, 2015	Jun. 30, 2020	Jun. 30, 2020	Jun. 30, 2019
RSU
Stock incentive plan
Vested stock units awarded (in shares)						3,481,000
RSUs granted (in shares)						3,739,000
PRSU
Stock incentive plan
RSUs granted (in shares)						274,000
Stock incentive plans
Stock incentive plan
Vesting period						4 years
Stock incentive plans | RSU
Stock incentive plan
Vesting period						3 years
Stock incentive plans | Stock options
Stock incentive plan
Vesting period						4 years
Vesting rate upon anniversaries						25.00%
Monthly vesting rate thereafter						2.08%
Options granted (in dollars per share)						$ 10.10	$ 14.52
Total grant date fair value of options to purchase common stock vested						$ 1.8	$ 2.5
Exercised, aggregate intrinsic value						$ 3.7	4.5
Stock incentive plans | First anniversary | RSU
Stock incentive plan
Vesting rate upon anniversaries						33.33%
Stock incentive plans | Second anniversary | RSU
Stock incentive plan
Vesting rate upon anniversaries						33.33%
Stock incentive plans | Third anniversary | RSU
Stock incentive plan
Vesting rate upon anniversaries						33.33%
2019 Incentive Compensation Plan | PRSU
Stock incentive plan
Vesting period	1 year	2 years
Vested stock units awarded (in shares)						800,000
RSUs granted (in shares)	300,000
Fair value	$ 3.6				$ 3.6	$ 3.6
Shares reserved for future issuance	200,000				200,000	200,000
2015 Employee Stock Purchase Plan
Stock incentive plan
Shares reserved for future issuance	1,200,000				1,200,000	1,200,000
Purchase price of common stock of the lesser of fair market value on the purchase date or the last trading day preceding the offering date				85.00%
Cash received from payroll deductions						$ (1)
Minimum | 2010 Plan
Stock incentive plan
Employees holding voting rights of all classes of stock						10.00%
Exercise price of options on common stock						110.00%
Minimum | 2019 Incentive Compensation Plan | PRSU
Stock incentive plan
Potential payout, target percentage	0.00%
Maximum | 2010 Plan
Stock incentive plan
Term of options granted						10 years
Maximum | 2019 Incentive Compensation Plan | PRSU
Stock incentive plan
Potential payout, target percentage	100.00%
Singular Bio | Stock incentive plans
Stock incentive plan
RSUs granted (in shares)						4,400,000
Singular Bio | Stock incentive plans | RSU
Stock incentive plan
Fair value			$ 90				90
Singular Bio | Stock incentive plans | PRSU
Stock incentive plan
Vesting period			12 months			18 months
Vested stock units awarded (in shares)					600,000	600,000
Fair value	$ 54.4		$ 45		$ 54.4	$ 54.4	$ 45
Singular Bio | Stock incentive plans | First anniversary | RSU
Stock incentive plan
Vesting rate upon anniversaries			33.33%			33.33%
Singular Bio | Stock incentive plans | Second anniversary | RSU
Stock incentive plan
Vesting rate upon anniversaries			33.33%			33.33%
Singular Bio | Stock incentive plans | Third anniversary | RSU
Stock incentive plan
Vesting rate upon anniversaries			33.33%			33.33%

Stock incentive plans - Schedul

Stock incentive plans - Schedule of activity under the plans (Details) - Stock incentive plans - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	6 Months Ended	12 Months Ended
	Jun. 30, 2020	Dec. 31, 2019
Stock options
Activity under the plan
Shares available for grant, beginning balance (in shares)	5,444
Stock options outstanding, beginning balance (in shares)	3,542
Additional shares reserved (in shares)	5,027
Options granted (in shares)	282
Options exercised (in shares)	(308)
Shares available for grant, ending balance (in shares)	7,376	5,444
Stock options outstanding, ending balance (in shares)	3,516	3,542
Weighted-Average Exercise Price
Balance at the beginning of the period (in dollars per share)	$ 9.49
Options granted (in dollars per share)	16.28
Options exercised (in dollars per share)	7.04
Balance at the end of the period (in dollars per share)	$ 10.26	$ 9.49
Additional information
Exercisable, number of shares	2,940
Exercisable, weighted-average exercise price (in dollars per share)	$ 9.30
Weighted-average remaining contractual life	6 years 1 month 6 days	6 years 1 month 6 days
Aggregate Intrinsic Value	$ 70,414	$ 24,966
Exercisable, weighted-average remaining contractual life	5 years 6 months
Exercisable, aggregate intrinsic value	$ 61,695
Vested and expected to vest
Number of shares	3,414
Weighted-average exercise price (in dollars per share)	$ 10.08
Weighted-average remaining contractual life	6 years
Aggregate intrinsic value	$ 68,992
Time-based RSUs and PRSUs
Activity under the plan
Granted (in shares)	(3,150)
Cancelled (in shares)	337

Stock incentive plans - Summary

Stock incentive plans - Summary of RSU activity (Details) shares in Thousands	6 Months Ended
	Jun. 30, 2020$ / sharesshares
RSU
Number of Shares
Balance at the beginning of the period (in shares) | shares	8,885
Granted (in shares) | shares	3,739
Vested stock units awarded (in shares) | shares	(3,481)
Cancelled (in shares) | shares	(337)
Balance at the end of the period (in shares) | shares	8,217
Weighted- Average Grant Date Fair Value Per Share
Balance at the beginning of the period (in dollars per share) | $ / shares	$ 15.17
Granted (in dollars per share) | $ / shares	15.35
Vested (in dollars per share) | $ / shares	15.32
Cancelled (in dollars per share) | $ / shares	18.83
Balance at the end of the period (in dollars per share) | $ / shares	$ 14.19
Time-based RSUs and PRSUs
Number of Shares
Granted and adjusted (in shares) | shares	(863)
Weighted- Average Grant Date Fair Value Per Share
Granted (in dollars per share) | $ / shares	$ 23.58
PRSU
Number of Shares
Granted (in shares) | shares	274
Weighted- Average Grant Date Fair Value Per Share
Granted (in dollars per share) | $ / shares	$ 16.17

Stock incentive plans - Summa_2

Stock incentive plans - Summary of stock based compensation expense (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Stock-based compensation
Total stock-based compensation expense	$ 51,846	$ 14,317	$ 81,124	$ 19,540
Cost of revenue
Stock-based compensation
Total stock-based compensation expense	2,356	2,205	3,217	2,856
Research and development
Stock-based compensation
Total stock-based compensation expense	41,565	6,767	63,769	8,572
Selling and marketing
Stock-based compensation
Total stock-based compensation expense	3,298	2,914	5,120	4,157
General and administrative
Stock-based compensation
Total stock-based compensation expense	$ 4,627	$ 2,431	$ 9,018	$ 3,955

Net loss per share - Schedule o

Net loss per share - Schedule of earnings per share, basic and diluted (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Earnings Per Share [Abstract]
Net loss	$ (166,403)	$ (48,676)	$ (264,930)	$ (86,353)
Shares used in computing net loss per share, basic and diluted	129,023	90,863	112,765	85,148
Net loss per share, basic and diluted (in dollars per share)	$ (1.29)	$ (0.54)	$ (2.35)	$ (1.01)

Net loss per share - Schedule_2

Net loss per share - Schedule of antidilutive securities excluded from computation of earnings per share (Details) - shares shares in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Antidilutive shares excluded from diluted net loss per share
Total shares of common stock equivalents (in shares)	24,560	9,002	24,176	10,008
Shares of common stock subject to outstanding options
Antidilutive shares excluded from diluted net loss per share
Total shares of common stock equivalents (in shares)	3,416	3,669	3,447	3,714
Shares of common stock subject to outstanding warrants
Antidilutive shares excluded from diluted net loss per share
Total shares of common stock equivalents (in shares)	369	593	429	601
Shares of common stock subject to outstanding RSUs
Antidilutive shares excluded from diluted net loss per share
Total shares of common stock equivalents (in shares)	6,403	4,569	5,716	4,350
Shares of common stock subject to outstanding PRSUs
Antidilutive shares excluded from diluted net loss per share
Total shares of common stock equivalents (in shares)	2,379	0	2,586	0
Shares of common stock pursuant to ESPP
Antidilutive shares excluded from diluted net loss per share
Total shares of common stock equivalents (in shares)	313	46	318	55
Shares of common stock underlying Series A convertible preferred stock
Antidilutive shares excluded from diluted net loss per share
Total shares of common stock equivalents (in shares)	125	125	125	1,288
Shares of common stock subject to convertible senior notes exercise
Antidilutive shares excluded from diluted net loss per share
Total shares of common stock equivalents (in shares)	11,555	0	11,555	0

Geographic information - Schedu

Geographic information - Schedule of revenue by country (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Geographic information
Total revenue	$ 46,191	$ 53,475	$ 110,439	$ 94,028
United States
Geographic information
Total revenue	43,334	50,368	103,140	88,013
Canada
Geographic information
Total revenue	797	882	2,016	1,847
Rest of world
Geographic information
Total revenue	$ 2,060	$ 2,225	$ 5,283	$ 4,168